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ABSTRACT
Prostate cancer (PCa) is one of the most commonly diagnosed diseases and the second
leading cause of cancer deaths among men worldwide. Its growth is dependent upon androgen
receptor (AR) signaling and the mainstay for treatment is hormone-ablation therapy using
antiandrogens and/or androgen-deprivation therapies (ADT).

Treatment of PCa with

antiandrogens and/or ADT are initially effective; they act to repress the AR by directly
competing with androgens for the ligand binding domain (LBD) and prevent activation of the
receptor resulting in tumor regression.

Unfortunately, the resistance to these treatments

invariably emerges and results in a much more aggressive form of tumor that is androgenindependent termed castration-resistant prostate cancer (CRPC). Given the AR signaling axis is
still active in CRPC and the heat shock protein (Hsp) 90-associated co-chaperone 52-kDa
FK506-binding protein (FKBP52) plays important positive regulatory roles in AR,
glucocorticoid receptor (GR), and progesterone receptor (PR) functions, FKBP52 represents a
promising therapeutic candidate for treating PCa. Structure-based in silico drug screens of a
virtual compound library representing lead-like molecules identified a list of 40 molecules that
are predicted to bind to FKBP52. Functional screens of these hit compounds identified a lead
molecule, termed GMC1, that inhibits FKBP52-enahnced AR, GR, and PR function, and impairs
AR-mediated activation of PSA promoter activity. Additionally, our data show that GMC1
reduces endogenous androgen-dependent AR-regulated gene expression and PSA secretion.
Finally, GMC1 impedes androgen-stimulated prostate cancer cell proliferation through
destabilization of AR resulting in disruption of the hormone-binding ability of the receptorHsP90-FKBP52 complex. Preclinical evaluations of GMC1 were performed by administering
co-solvent GMC1 formulation via intratumoral injection into human xenograft mouse model.
The data demonstrate promising potential in treating CRPC; tumor volumes are significant
reduced compare to vehicle-treated controls. This proof-of-principle data in whole animal model
further establishes FKBP52 PPIase-targeting drugs as effective therapies for PCa and warrant
vii

further preclinical development. Together, these findings demonstrate that FKBP52 is a viable
target for PCa treatment and will lead to the development of more potent and effective drugs for
the treatment of CRPC.

Given GMC1’s unique mechanism of action, GMC1 is likely to

circumvent AR-based therapy-induced resistance mechanisms, thereby filling a major unmet
need in prostate cancer therapy.
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CHAPTER 1: INTRODUCTION
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The proper folding and activity of steroid hormone receptors (SHRs) requires no less than
twelve proteins and at least three distinct chaperone/receptor complexes. Many of these
chaperones and co-chaperones are attractive targets for the treatment of a variety of diseases.
The heat shock protein (Hsp) 90-associated 52-kDa FK506-binding protein (FKBP52) is of
particular interest as FKBP52 is a known positive regulator of androgen (AR), progesterone
(PR), and glucocorticoid receptor (GR) activity, and serves as an attractive therapeutic target for
any disease that depends on a functional AR, PR, and/or GR signaling pathway. Much progress
has been made in understanding the mechanisms by which FKBP52 regulates receptor signaling
and the resulting roles it plays, not only in hormone-dependent processes, but also in endocrineindependent functions, including cell architecture, neurodifferentiation, and metal transport, etc.
This chapter summarizes the current understanding of chaperone-dependent SHR folding,
FKBP52 interactions within the receptor-chaperone complex, FKBP52 contributions to health
and disease, and FKBP52’s potential as a therapeutic candidate for hormone-dependent and
hormone-independent diseases. Furthermore, based on the progress that has been made in
understanding residues and/or domains critical for function, we discuss the most promising
strategies for the therapeutic targeting of FKBP52.
1.1 Chaperone-Mediated Steroid Hormone Receptor Maturation
Steroid hormones are small lipophilic molecules whose functions are mediated by
intracellular receptor proteins termed steroid hormone receptors including AR, PR, GR,
mineralocorticoid (MR), and estrogen receptors (ER). These receptors are ligand-regulated
transcription factors that are required to be in continuous interactions with molecular chaperones
and co-chaperones to establish and maintain their functionally mature conformations necessary
for hormone binding and the subsequent control of a diverse array of physiological processes
and/or promotion of disease states. The activation and maturation of the SHRs depend on
interactions within the Hsp90-mediated chaperoning pathway, which is an ordered, dynamic, and
cooperative series of events that involves multiple chaperone and co-chaperone components.
2

The heat shock proteins Hsp40, Hsp70, and Hsp90 in addition to the co-chaperones
Hsp70/Hsp90 organizing protein (HOP) and p23 are minimally required for efficient SHR
folding and maintenance of receptor hormone binding ability in vitro. Furthermore, SHRs must
chronologically cycle through three distinct complexes, each with different chaperone and cochaperone compositions, to reach their final active conformations (Fig. 1.1) [1-12]. While this
chapter focuses on FKBP52 as a therapeutic target, it is important to point out that the
chaperone-dependent folding, activation, and regulation of SHRs presents a variety of
opportunities for therapeutic intervention.

Thus, we also discuss the chaperone-dependent

folding and activation pathway, and other potential targets for the disruption of SHR folding in
detail below.
1.1.1 Early Complex
Little is known about the SHR folding process prior to nascent chain folding as the
receptors emerge from the ribosome. However, in vitro receptor-chaperone complex assembly
studies suggest Hsp40 and Hsp70 binding as the first step in the recognition of PR and GR,
respectively, in the Hsp90-dependent chaperoning pathway through binding to a single site in the
receptor ligand binding domain (LBD), yet the exact binding site has not been identified [4, 13].
Regardless of the exact details, an early primary role for Hsp70 in receptor maturation is clear.
The nascent SHRs are bound by Hsp70 in an adenosine triphosphate (ATP)-dependent manner.
The J-domain of Hsp40 stimulates Hsp70 ATPase activity leading to a conformational change
resulting in a tight association of Hsp70 with the substrate [4, 14]. Thus, the early complex of
the chaperoning pathway consists of Hsp70 and Hsp40 components that prime the receptor for a
second ATP-dependent interaction with Hsp90 to form the intermediate complex [4, 15]. A
surveillance system in eukaryotic cells also functions at this stage in the folding cycle to
modulate “protein triage” decisions that regulate the balance between protein folding and
degradation for chaperone substrates [16].
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Figure 1.1: Chaperone-Mediated Steroid Hormone Receptor Folding
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Fig. 1.1: Chapterone-Mediated Steroid Hormone Receptor Folding. Receptors associate
with chaperones and co-chaperones as they cycle through early, intermediate, and mature
complexes offering a variety of opportunities for therapeutic intervention.

Early complex

assembly is initiated upon Hsp40 binding to the nascent receptor polypeptide residing in the
cytosol. Hsp40 recruits Hsp70 where the fate of the nascent polypeptide is determined to
proceed with the intermediate complexes or towards proteasomal degradation. The carboxyl
terminus of CHIP is an E3 ubiquitin ligase that, along with BAG proteins, directs misfolded
receptors towards the ubiquitin and proteasomal degradation pathways. In the intermediate
complex SGTA binds to Hsp70. Hsp70 then recruits HIP and HOP forming a bridge for Hsp90’s
binding into the complex. As the nascent polypeptide travels through the intermediate complex
the immunophilins (I) bind in a competitive fashion to Hsp90 allowing for a conformational
change. Further, the mature complex forms as HIP, HOP, and SGTA dissociate and p23 binds to
stabilize the receptor-Hsp90 complex in the mature conformation to which hormone can bind
with high affinity. The receptor is then able to translocate to the nucleus, dimerize and bind to
hormone response elements to initiate gene transcription.

5

1.1.2 Protein Quality Control: Ubiquitin/Proteasomal System
Carboxyl terminus of Hsp70-interacting protein (CHIP) is a tetratricopeptide repeat
(TPR)-containing co-chaperone that functions as a U-box dependent E3 ubiquitin ligase [17, 18].
It binds to both Hsp70 and Hsp90 through its TPR domain and inhibits the folding activity of the
chaperones by confining the chaperone in an ATP-bound conformational state [16, 18]. CHIP
plays a pivotal role in the conversion of the chaperone complex from a protein-folding apparatus
to a protein-degradation machine by promoting the ubiquitination of chaperone substrates and
stimulates their degradation by targeting them to the ubiquitin/proteasome pathway [16, 19]. In
addition, biochemical studies have demonstrated that CHIP participates in triage decisions based
on stochastic sampling of chaperone-bound substrate complexes [20]. CHIP randomly samples
the chaperone-bound substrates and the ones that cannot be folded efficiently and/or correctly
would consequently stay in the chaperoning cycle longer and eventually be ubiquitinated and
targeted for degradation [20].

In addition to CHIP, the co-chaperone Bcl-2-associated

athanogene 1 (BAG-1) has also been reported to act as a coupling factor between the Hsp70
chaperone system and the protein degradation machinery [21, 22]. BAG-1 binds to Hsp70 via its
C-terminal BAG domain while its N-terminal ubiquitin-like domain associates with the ATPase
domain of the chaperones leading to the release of the ubiquintylated substrate and, at the same
time, serves as a physical link between the Hsp70 and the 26S proteasome [21, 23-25]. Thus,
BAG-1 plays a dual role, both as a scaffolding factor at the proteasome and as a substrate release
factor of Hsp70. It is worth noting that CHIP cooperates with BAG-1 in targeting Hsp70
substrates to the ubiquitin/proteasome system [26]. CHIP associates with Hsp70 via its TPR
domain and mediates ubiquitin attachment to the aberrantly folded substrate bound to the
chaperone by recruiting and binding of the E2 ubiquitin-conjugating enzyme to its C-terminal Ubox. At the same time, BAG-1 binds the Hsp70 via its BAG domain and utilizes its ubiquitinlike domain for releasing of the ubiquitylated substrate from the chaperone and targets it to the
26S proteasome where their de-ubiquitylation, unfolding, and degradation occur [26].
Interestingly, recent biochemical assays indicated that S100 proteins bind to TPR domains and
6

interfere with CHIP/Hsp70 interactions leading to suppression of CHIP-dependent ubiquitination
and degradation [27]. Therefore, the association of the S100 proteins with CHIP provides a
calcium (Ca2+)-dependent regulatory mechanism for the ubiquitination and degradation of
intracellular proteins by the CHIP-proteasome pathway.
1.1.3 Intermediate Complex
Those substrates deemed suitable for continued folding, as described above, are shuttled
to intermediate complexes. Hsp70-interacting protein (Hip) facilitates intermediate complex
formation by interacting with Hsp70 through its N-terminal TPR domain, which prevents
dissociation of ADP from Hsp70. Since ADP-bound Hsp70 binds substrate with higher affinity,
the binding of Hip with Hsp70 enhances the interaction of SHR with Hsp90 and Hop [1, 28-32].
Hop is another member of the TPR-containing co-chaperone family, which contains a
specialized and conserved TPR-clamp domain consisting of TPR1, TPR2A, and TPR2B. Hop
functions as a scaffold protein between the Hsp90 dimer and Hsp70 by their binding to its
TPR2A and TPR1/TPR2B motifs, respectively, enabling the client transfer between the
chaperones [1, 6, 33, 34]. Recent studies have shown one Hop bound to Hsp90 dimer is
sufficient to stabilize the dimer in an open conformation. In this intermediate complex, Hop
binding to the TPR-acceptor site introduces a steric hindrance that prevents the other C-terminal
TPR-acceptor site on the Hsp90 dimer to be bound.
Apart from the C-terminal TPR-acceptor motif, a novel site for TPR co-chaperone
interaction near the N-terminal ATP binding domain of Hsp90 has recently been discovered [35].
This TPR-acceptor motif on the Hsp90 dimer is preferentially occupied by TPR-containing cochaperones containing a PPIase domain and the interaction leads to the formation of an
asymmetric Hsp90 intermediate complex [36-38]. GCUNC-45 is such an example of a PPIase
that binds to Hsp90 via its TPR domain forming an asymmetric intermediate complex during PR
chaperoning. Yeast two-hybrid analyses have revealed that GCUNC-45 directly interacts with a
novel TPR-acceptor site near the N-terminus of Hsp90 [35]. The primary function of N-terminal
7

domain (NTD) of Hsp90 is to bind ATP, which then induces an interaction between the NTDs of
the Hsp90 dimer. This dimerization is further facilitated by the binding of activator of Hsp90
ATPase homologue 1 (Aha1) to the middle domain (MD) of the chaperone leading to the
repositioning of a catalytic loop of this domain that interacts with the γ phosphate of ATP bound
in the NTD [39, 40]. Mutational analyses have revealed that the GCUNC-45 binding motif on
Hsp90 was generated by a spatial positioning of noncontiguous residues in the ATP binding
domain [41]. Thus, it is suggested that binding of GCUNC-45 to the novel TPR-acceptor site
near the N-terminus of Hsp90 may result in a spatial re-orientation between the NTD and MD
leading to inhibition of ATPase activity of the chaperone by blocking the binding of Aha1 to
MD, even though the two proteins do not share a common binding site [35, 41]. Thus, GCUNC45 enters the chaperoning pathway at the intermediate stage forming an asymmetric intermediate
complex with Hsp90/Hop intermediate complex and blocks progression of the PR complex to the
next step with the purpose of allowing time for additional needed chaperoning events to occur.
This confined regulation event by GCUNC-45 can be reversed in the presence of another PPIase
TPR-containing co-chaperone, such as FKBP52, whose structure and function will be discussed
in further detail below. PR assembly studies have demonstrated that GCUNC-45 functions
upstream of FKPB52 during the chaperoning [35].

In addition, FKBP52 can reverse the

confined inhibition by GCUNC-45 and promotes the progression of the PR chaperoning cycle
toward the hormone binding competent mature state by competitively binding with GCUNC-45
for the novel TPR binding site near the N-terminus of Hsp90 [35, 41]. What induces the
displacement of GCUNC-45 is unknown; it could be a response to specific signals and/or
imbalance in intracellular homeostasis during the receptor chaperoning. It has recently been
reported that S100 proteins, which are a subfamily of the EF-hand type Ca2+-sensing proteins,
compete with Hsp90 for the TPR domain of FKBP52 and cyclophilin 40 (Cyp40), which is
another TPR-containing PPIase protein that is able bind to the N-terminal TPR acceptor site, in a
Ca2+-dependent manner [41, 42]. Given that GCUNC-45, FKBP52, and Cyp40, but not Hop,
bind to S100 suggests that only a selective subgroup of TPR co-chaperones is able to bind to the
8

N-terminal TPR-acceptor site. S100 proteins regulate this subgroup of co-chaperones by binding
to the TPR domain to competitively inhibit the FKBP52-Hsp90 and Cyp40-Hsp90 interactions.
Interestingly, studies have shown that S100 proteins can also regulate the Hsp70/Hop/Hsp90
intermediate complex in a Ca2+-dependent manner by binding to the TPR domains of Hop, hence
disrupting the Hop-Hsp70 and Hop-Hsp90 interactions [43]. No matter what the details, it is
undeniable that the presence of two Hsp90 sites for TPR protein interaction provides additional
flexibility and control in modulating the Hsp90 co-chaperones and its clients during the
chaperoning process.
Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) is a cochaperone that interacts directly with Hsp70, but weakly with Hsp90, via its C-terminal TPR
domain and predominantly precipitates with Hsp70 from cell lysates [44, 45]. Interestingly,
SGTA lacks a PPIase domain, which is a common feature among the related TPR proteins.
Studies have shown that interaction with SGTA enhances Hsp70’s and/or Hsp90’s substrate
binding affinity and the ATPase activity of the chaperones by favoring their ADP-dependent
association with client molecules [44, 46, 47]. Studies by Buchanan et al. demonstrated that the
binding of dihydrotestosterone (DHT) induces the dissociation of SGTA from the hinge region
of AR, and conversely, its overexpression decreases the capacity of the hormone to mediate
receptor transport to the nucleus [48]. In agreement with their experiments, our lab has reported
that SGTA associates not just with AR, but also with GR and PR to regulate receptor activity.
Furthermore, knockdown/deletion of SGTA enhances receptor activity, whereas the
overexpression of the co-chaperone suppresses receptor activity [45]. Taken together, the data
suggest that SGTA participates in the Hsp70/Hsp90-mediated intermediate complex and plays a
quality control role in the chaperone-dependent receptor maturation. It suggests that SGTA
enters the chaperoning pathway at the intermediate stage forming an intermediate complex
and/or asymmetrical intermediate complex with Hsp70, Hsp90, Hop, and receptor substrate by
interacting with the hinge region of the receptor and binding to Hsp70 via its TPR domain.
However, the binding of SGTA to the hinge region affects receptor nuclear transport since the
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receptor nuclear targeting sequence overlaps with the SGTA binding site [49].

Thus, this

putative model provides an explanation for the fact that SGTA is a negative regulator of the
receptors and its overexpression suppresses receptor activity, abrogates the regulation of receptor
function by FKBP52, and decreases ligand-mediated receptor transport to nucleus.
1.1.4 Mature Complex
Biophysical studies using fluorescence resonance energy transfer (FRET) have shown
that, once the temporary inhibition of Hsp90 ATPase activity imposed during the asymmetrical
intermediate complex has been removed, ATPs quickly bind and secure the nucleotides by
closing the ATP lids resulting in conformational changes in Hsp90 leading to the closing of the
NTDs [50, 51]. This structural modification reduces the affinity of Hop for the assembly
resulting in the exiting of the adaptor protein and its associated Hsp70. At the same time, Aha1
binds the MD to facilitate the domain repositioning and interaction with NTDs [39]. The
dimerized N-terminal conformation recruits the p23 co-chaperone and one of several TPRcontaining PPIases (e.g. FKBP52) [52]. p23 is a small acidic protein containing an unstructured
C-terminal tail, which is essential for its intrinsic chaperone activity [53, 54]. Additionally, it is
a conformation-specific co-chaperone that binds exclusively to the closed conformation of
Hsp90 [55, 56]. Furthermore, p23 facilitates the maturation of client proteins (e.g. SHRs) by
stabilizing the closed conformation of Hsp90 [7, 52, 53]. In fact, studies have shown that the
presence of p23 can partially inhibit Hsp90 ATP hydrolysis, which is indispensable for the
release of the client protein, such as SHRs [10, 57-61]. It is worth noting that it is in this active
Hsp90/p23/TPR-containing PPIase mature complex that the SHR is capable of high affinity
hormone binding. Upon ligand binding, the receptor dimerizes and translocates to the nucleus,
which then binds to the hormone response element (HRE), and in turn, recruits other coregulators resulting in regulation of various physiological functions such as development,
differentiation, metabolic homeostasis, and reproduction. Ligand binding to the receptor has
long been thought to be the trigger that stimulates release of the receptor from the chaperone
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complex allowing receptor translocation to the nucleus. However, studies have shown that
ligand-bound GR is able to undergo dynamic cycling with the chaperone machinery, which is
essential for receptor trafficking to, and within, the nucleus [62, 63]. In the absence of ligand
binding, the mature complex stays active until the hydrolysis of ATP followed by the
dissociation of the NTDs of Hsp90 leading to the release of p23, the TPR-containing PPIase, and
the folded client protein from the chaperone [37, 64]. Finally, the free hormone receptors reenter the chaperoning cycle by binding to Hsp40 and Hsp70 for refolding.
1.2 THE FKBP52 CO-CHAPERONE
FKBP52 has been identified as one of the TPR-containing PPIase co-chaperones that are
involved, together with Hsp90 and p23, in the mature SHR/chaperone complex. It is in this form
of the complex that the SHRs are capable of high affinity hormone binding and consequently
translocate to the nucleus to modulate transcriptional activity. While FKBP52 is not an absolute
requirement for SHR hormone binding and signaling in vitro [9, 65, 66], it is required for
efficient AR, GR, and PR hormone binding and activity at low concentrations of hormone [67,
68]. Thus, it is assumed that receptor activity in vivo is dependent on FKBP52 at physiological
hormone concentrations. FKBP52 belongs to a family of immunophilins that is characterized by
a conserved PPIase domain, which has peptidyl-prolyl cis/trans isomerase activity and also
serves as a binding site for the immunosuppressive drug, FK506 [69].

Sequence data,

hydrophobic cluster analysis, and crystallographic structures of overlapping FKBP52 fragments
suggested the protein is composed of four distinct domains (Fig. 1.2a) [70-73]. The first two
consecutive FKBP domains, FK1 and FK2, are structurally similar to the PPIase domain of 12kDa FK506-binding protein 12 (FKBP12); which includes a functional site for PPIase activity
(FK1) and a PPIase-like domain that lacks PPIase activity (FK2) [74]. Three TPR motifs occupy
the third structural domain [75] while the fourth C-terminal domain (C-Terminal Tail) contains a
motif important for binding Hsp90 and putative calmodulin (CaM) binding sites [71]. In the
following sections, we will discuss the current understanding of FKBP52 structural features and
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how those features contribute to FKBP52 interactions and functions within the SHR/chaperone
complex.
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Figure 1.2: Structure of FKBP52 and the Putative FKBP52 Regulatory Surfaces on AR

13

Fig. 1.2: Structure of FKBP52 and the Putative FKBP52 Regulatory Surfaces on AR. (a) A
composite of two partial structures for human FKBP52 (protein databank number 1Q1C and
1P5Q) showing the locations of the functional domains of FKBP52. The individual domains as
well as regions of functional importance are individually colored. The TPR domain (green)
mediates binding to Hsp90 via the MEEVD motif at the extreme C-terminus of Hsp90. The FK2
domain (red) is structurally similar to FK1, but lacks PPIase activity and the ability to bind to the
immunosuppressive ligand FK506. The FK linker (teal), which connects the FK1 (blue) and
FK2 (red) domains, contains a casein kinase II (CKII) phosphorylation sequence that, when
phosphorylated, abrogates FKBP52 function due to the re-orientation of FK1 domain
conformation. The FK1 domain (blue) is the primary regulatory domain for SHRs that displays
FK506 binding and PPIase activity.
potentiation.

FK1 is also important for FKBP52-mediated receptor

In particular, the proline-rich loop (yellow), also known as the β4-β5 loop,

overhanging the PPIase pocket of the FK1 domain is crucial for receptor regulation and has been
proposed to serve as a functionally important interaction surface. (b) A ribbon model of the
FKBP52 FK1 domain is shown. The β4-β5 loop (yellow) and the β3 bulge (orange), and their
respective residues (same colors), are structurally the most divergent regions at the periphery of
the PPIase pocket between FKBP52 and its paralog, FKBP51.

Mutational changes in the

residues in and/or around the loop and bulge, such as residues F67/D68 (purple), can induce
conformational changes in the pocket resulting in the obstruction of FKBP52-mediated receptor
activity. (c) The left panel is a surface rendering of the AR ligand binding domain showing the
relative locations of the putative FKBP52 regulation sites including BF3 (blue), the H1-H3 loop
(green), and AF2 (purple). The right panel is a ribbon representation of the AR ligand binding
domain, with dihydrotestosterone (teal) bound, showing the location of the mutated residues in
relation to the BF3 surface. F673 (yellow) and P723 (orange) are within the BF3 surface and
C806 (red) is buried directly below the surface. Mutations of these residues within the BF3
surface result in increased dependence on FKBP52 for function. This is also the site to which the
recently characterized inhibitor of FKBP52-regulated AR activity, MJC13, is predicted to bind.
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1.2.1 C-Terminal Tail
The C-terminal 60 amino acids, more specifically a 20-amino acid consensus sequence
motif within this region, play an important role for Hsp90 binding. Within this consensus
sequence motif is an 11-amino acid conserved region (charge-Y motif), which can be found in
other human TPR-containing Hsp90 co-chaperones. The charge-Y motif is defined by the
sequence -+-+XΦYXXMF, where - represents Glu or Asp, + represents Lys or Arg, Φ represents
a hydrophobic amino acid, and X represents any amino acid [76]. In addition to the charged-Y
motif, the extreme C-terminal amino acids also have a significant impact on Hsp90 binding [76].
Thus, the C-terminal regions outside the core TPR regions are important for optimum FKBP52
binding to Hsp90. The extreme C-terminus of FKBP52 (amino acid 400-458) also contains two
predicted CaM binding sites, which enables the protein to bind to CaM-Sepharose in a Ca2+dependent manner [71]. Amino acid sequence analysis revealed the presence of PEST sequences
within the predicted sites, which are generally present in CaM-binding proteins [71, 77].
However, the biological function of these CaM binding sites is still unknown.
1.2.2 TPR Domain
The core TPR domain (amino acids 264-400) is composed of three tandem repeats of a
degenerate 34-amino acid motif. Crystallographic data have shown that each TPR motif adopts a
helix-loop-helix conformation and adjacent units stack in parallel to form a saddle-shaped
domain with a concave binding pocket that mediates protein-protein interactions [78-80]. It is in
this conformation that the TPR domain interacts with the MEEVD sequence in the extreme Cterminus of Hsp90. Mutagenesis studies have shown that peptide bonding is mediated through
electrostatic interactions by which the basic residues of the TPR domain interact with the
terminal aspartate of the pentapeptide [81]. The importance of the interaction is evident by the
fact that a single mutation (K354A) within the TPR can significantly reduce FKBP52 binding to
Hsp90 and abolished FKBP52-mediated potentiation of receptor function. In addition, FKBP52
domain truncation mutants demonstrated the TPR domain interaction with Hsp90 alone is
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necessary but not sufficient for FKBP52 regulation of SHR function [82]. Thus, the core TPR
domain is required for binding to Hsp90, but is inadequate for functional interaction with
SHR/Hsp90 complexes [83]. In fact, additional contacts involving charged and hydrophobic
residues upstream of the Hsp90 MEEVD sequence are required for enhancement of the affinity
and specificity of the interaction [47, 81]. The MEEVD pentapeptide is located at the extreme
C-terminus of Hsp90 is not the only interaction site for TPR domain-containing proteins. As
discussed above, recent studies have identified a novel region for TPR co-chaperone interaction
at the N-terminal ATP binding domain of Hsp90 [35, 41]. Mutational analyses demonstrated
that an acidic motif can be generated by a spatial positioning of noncontiguous residues (E42,
N46, D49, D52, L51, and D88) within and/or near the ATP binding pocket of Hsp90, which are
necessary for the binding of TPR domain-containing proteins [41]. As aforementioned, recent
biochemical studies have demonstrated S100 proteins compete with Hsp90 for FKBP52 TPR
domain in a Ca2+-dependent manner, hence regulating the immunophilin-Hsp90 complex
formation [42].
1.2.3 FK2 Domain
A direct functional role for the FK2 domain (amino acids 167 to 253) has not been
identified. It is a required domain to maintain the overall size and structure of the large FKBPs.
Despite the fact that it is structurally similar to FKBP12, it only has 26% sequence identity (44%
similarity) and marginal to no PPIase and drug-binding activities [74, 84]. Evolutionarily, FK2
appears to result from a duplication event of the FK domain. Mutagenesis and 51-kDa FK506binding protein (FKBP51)/FKBP52 chimeric protein studies demonstrated that there is a unique
interaction between the FK2 and TPR domains that is important for full SHR potentiating ability
[85]. Furthermore, deletion of three residues (D195, H196, and D197) within the FK2 domain of
FKBP51, a closely related protein that often antagonizes FKBP52-mediated functions, resulted
in abnormal integration of FKBP51 into PR complexes [84]. Thus, specific residues and/or
regions likely exist within FK2 that contribute directly to receptor regulation and possibly
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influence interactions with the components of the receptor-chaperone complex or the receptor
itself. Further studies are needed to define those critical residues and/or regions within FK2 that
are required for regulation of receptor activity.

Interestingly, FK2 contains a consensus

ATP/guanosine triphosphate (GTP)-binding sequence located between amino acids 199 and 222,
which can be phosphorylated in vitro in the presence of CaM in an ATP-dependent manner [86,
87], although the ability of FKBP52 to bind and hydrolyze nucleotide has not been demonstrated.
In fact, sequence and structural comparison data have demonstrated that FK2 displays structural
similarity to the TPR-containing homolog FKBP38, which is PPIase-inactive under basal
conditions but can be allosterically activated by CaM [88-91]. The fact that FKBP52 contains a
putative CaM-binding motif at the extreme C-terminus suggests that a similar allosteric
activation mechanism for the FK2 domain of FKBP52 exists.
1.2.4 FK Linker
The crystal structures of FKBP52 revealed a 9-amino acid long (amino acids 138-167)
flexible and solvent-accessible hinge region that connects the FK1 and the FK2 domains termed
the FK linker [92]. Within this linker region there is a consensus casein kinase II (CKII)
phosphorylation site (TEEED). FKBP52 is phosphorylated by CKII at T143, which is a major
phosphorylation site both in vivo and in vitro [93]. In silico modeling and structural analyses
revealed that T143 phosphorylation destabilizes the FK linker region and induces the allosteric
rearrangement of the FK1 domain [92-94]. FK1, as will be discussed in more detailed in the
following section, particularly the integrity of proline-rich loop that overhangs the PPIase pocket,
is a functionally important interaction surface that is required for FKBP52-mediated potentiation
of SHR response to hormone. Phosphorylation of T143 destabilizes the conformation of the
linker resulting in a widening of the architecture and introduces a steric hindrance by disrupting
the hydrogen-bonding network within the region causing a re-orientation within the linker [94].
Subsequently, weakening the FK1-FK2 contacts introduces a remodeling of the FK1 catalytic
domain by twisting a short α-helix that forms one side of the PPIase active site [94].
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Interestingly, tyrosine phosphorylation of FKBP52 influences adeno-associated virus type 2
(AAV) second-strand DNA synthesis by binding to single-stranded D-sequence-binding protein
within the virus’ terminal repeats limiting high-efficiency transgene expression, which may have
important implications for the optimal use of AAV vectors in human gene therapy [95, 96]. In
addition to the T143 phosphorylation site, a conserved negatively charged motif that was
predicted to be a complementary nuclear localization signal (NLS) recognition sequence also
localizes within the FK linker region [67]. FKBP52 is primarily localized in the nucleus with a
minority co-localizing with microtubules in the cytoplasm. Biochemical studies have shown that
antibodies raised against the NLS impede the hormone-mediated translocation of glucocorticoid
receptor (GR) in the nucleus [67]. This suggests that the sequence is required for anterograde
movement of FKBP52 to the cytoplasm where is associated with the Hsp90 heterocomplex to
facilitate the passage of the untransformed receptor through the nuclear pore.
1.2.5 FK1 Domain
The FK1 domain is located within the first 138 amino acids in the N-terminus of
FKBP52. Unlike the FK2 domain, FK1 contains a functional PPIase catalytic pocket located
between amino acids 4-137 that has enzymatic activity comparable to that of FKPB12 [70, 74].
In vitro studies demonstrated that FKBP52 selectively potentiates hormone-dependent gene
activation and hormone-binding affinity of AR, PR, and GR through interaction with the receptor
LBD [82, 97, 98]. Interestingly, it is not the enzymatic activity of the FK1 that is required for
receptor potentiation but the integrity of the PPIase pocket.

Furthermore, gain-of-function

mutagenesis studies identified a proline-rich loop that overhangs the catalytic pocket that is
critically involved in receptor interactions and enhanced hormone-mediated receptor activity
[85]. Structural comparison of the corresponding loop of FKBP52 and FKBP51 revealed the
most divergent regions in the domains between the two proteins are the β3 bulge and β4-β5 loop
(Fig. 1.2b). The β3 bulge occurs when there is a discontinuity in β-strand 3. In FKBP51, P76
(K76 in FKBP52) enforces a shift of the β3 bulge toward the β2-β3 loop, which forces E75
18

closer to the PPIase active site compared to D75 in FKBP52, thus, compromising FK1
architecture (Fig. 1.2b) [92, 99]. The same principle applies to the FD67DV double mutation,
which abolishes FKBP52–dependent potentiation of GR and AR (Fig. 1.2b).

Substantial

structural differences between FKBP51 and FKBP52 are also found at the tip of the β4-β5 loop;
FKBP52 has a proline at amino acid position 119 while FKBP51 has a leucine (Fig. 1.2b). P119
of FKBP52 projects outward to form a hydrophobic notch alone, while with the trans
configuration adopted by the P119-P120 peptide bond in the β4-β5 loop forms an important
functional interface that contributes to the enhancing effects of FKBP52 (Fig. 1.2b) [85, 92]. On
the contrary, L119 in FKBP51 projects inward and the cis conformation formed by the L119P120 bond impairs the potentiation of steroid receptor activity (Fig. 1.2b) [85, 92]. Gain-offunction mutagenesis studies corroborate this structural data; the FKBP51 mutation L119P
conferred significant receptor potentiating ability, whereas the converse P119L mutation in
FKBP52 decreased receptor potentiation. Interestingly, when a second residue, A116, in the β4β5 loop was also mutated, the FKBP51-A116V/L119P double mutant potentiated hormone
signaling similar to that of wild type FKBP52 [85]. These results all emphasize the importance
of architectural integrity of the proline-rich loop in acting as a critical interface for regulating
receptor interactions and activity.
1.3 FKBP52 IN STEROID HORMONE-REGULATED PHYSIOLOGY AN D DISEASE
Biochemical and cellular studies demonstrated that FKBP52 associates with the SHR
chaperone complex to specifically potentiate the activities of AR, GR, and PR.

The

physiological significance of these findings has been corroborated in fkbp52-deficient (52KO)
mouse models as phenotypes related only to androgen, glucocorticoid, and progesterone
insensitivity have been characterized to date (Fig. 1.3) [97, 100]. These studies firmly established
FKBP52 as a relevant factor in AR, GR, and PR-related physiology and disease.
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Figure 1.3: FKBP52-Regulated Hsp90-Dependent and Independent Physiology and Disease
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Fig. 1.3: FKBP52-Regulated Hsp90-Dependent and Independent Physiology and Disease.
The Hsp90-dependent roles for FKBP52 are largely mediated through FKBP52-Hsp90 complex
regulation of AR, GR, and PR signaling, which is independent of FKBP52 PPIase activity.
FKBP52 is an essential player in SHR/Hsp90-regulated physiological development and
reproductive success. The left side of the diagram depicts receptor-specific phenotypes that are
due to defective AR, GR, and PR signaling in the absence of FKBP52. Given the positive role of
FKBP52 in these receptor signaling pathways, FKBP52 may also serve as an attractive
therapeutic target for any disease that is dependent upon functional AR, GR, and PR mechanisms
(e.g. prostate cancer). Apart from the established roles of FKBP52 in SHR functions, the cochaperone is also involved in various Hsp90-independent biological functions, several of which
have been shown to require FKBP52 PPIase activity. The right side of the illustration shows that
the absence of FKBP52 could contribute to neurodegenerative tauopathies (Alzheimer’s Disease,
Pick’s Disease, fronto-temporal dementia and Parkinsonism linked to chromosome 17 (FTDP),
progressive supranuclear palsy), disruptions in Cu and Ca2+ homeostasis and immune system,
and inhibition of AAV DNA synthesis resulting in inefficient transgene expression from
recombinant AAV vectors used in gene therapy.
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1.3.1 Phenotypes in fkbp52-Deficient Mice
The observed reproductive phenotypes observed in the 52KO mice are attributed to the
loss of SHR activities. Male 52KO mice are infertile and display abnormal virilization with
persistent nipples, ambiguous external genitalia, and dysgenic seminal vesicles and prostate [97,
100], which are consistent with androgen insensitivity in these tissues. Despite the androgen
insensitivity, the testicular morphology, descent, histology, and spermatogenesis develop
normally with unimpaired androgen production and release from the testes [97], which might
suggest that testosterone levels produced locally within the testis is high enough to compensate
for significantly reduced AR activity. Alternatively, it is possible that a factor present within the
testis can complement for the loss of FKBP52. Despite no observable defect in spermatogenesis,
sperm isolated from the organ displayed abnormal tail morphology and reduced motility, which
is not androgen-dependent [101]. These findings may reflect FKBP52’s ability to bind to dynein
motor proteins [67].
In contrast to what is observed in 52KO male mice, 52KO females have no gross
morphological abnormalities and display normal ovulation and fertilization, yet they are
completely infertile [102]. The infertility is the result of failure in embryonic implantation and
decidualization [98, 102-104].

The ER and PR are critical factors mediating embryonic

implantation. Interestingly, the absence of FKBP52 leads to a selective failure of receptor
function resulting in female mice sterility. In fact, FKBP52 does not alter ER function in cellular
studies and 52KO mice show no signs of estrogen insensitivity. Rather, the implantation and
decidualization failures result from an inability of the uterus to mount a decidualization response
to progesterone due to progesterone insensitivity and uterine defects [102]. This implantation
failure is also a result of an increased uterine oxidative stress and a reduced level of the
antioxidant peroxiredoxin-6 (PRDX6) [104, 105]. Furthermore, the loss of FKBP52 promotes
the growth of endometriotic lesions due to increased cell proliferation, inflammation, and
angiogenesis [106]. These events are largely dependent upon progesterone actions, and, along
with the corroborative data from both molecular and cellular studies, this confirms that FKBP52
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is required for full PR activity in vitro and in vivo. Taken together, these data firmly establish a
critical role for FKBP52 in reproductive development and success in both male and female mice
and these roles can be traced to support of AR and PR functions.
Due to the partial embryonic lethality in null 52KO mice [107], heterozygous fkbp52deficient (52+/-) mice were generated to determine the in vivo roles for the co-chaperone in GRmediated physiology. 52+/- mice manifested phenotypes associated with defective GR signaling
including increased susceptibility to high-fight diet induced hepatic steatosis, hyperglycemia, and
hyperinsulinemia.

They also displayed glucocorticoid resistance and behavioral alterations

under basal and chronic stress conditions [108, 109].
As previously discussed, FKBP52 does not alter ER function in cellular studies and
52KO mice do not manifest signs of estrogen insensitivity. However, studies have reported that
FKBP52 expression levels are associated with ERα, which implicates FKBP52 as a potential
factor in breast cancer [110]. Treatment of breast cancer cells with estradiol resulted in an
increased half-life of FKBP52 mRNA, and both FKBP52 gene and protein expressions have
been reported to be significantly up-regulated and in ERα-positive cell lines as compared with
ERα-negative cell lines [110, 111]. Furthermore, the FKBP52 gene is epigenetically silenced by
methylation in ER-negative, but not in ER-positive, breast cancer cells [112]. Taken together,
these studies have identified FKBP52 as a relevant factor in ERα-positive breast cancer. In
addition, recent studies suggest an increased reliance on AR signaling in triple negative breast
cancer [113]. Given the known roles for FKBP52 in AR signaling, these studies implicate
FKBP52 as a potential target in triple negative breast cancer.
1.3.2 FKBP52 in Hsp90-Independent Physiology and Disease
Apart from the well-established roles of FKBP52 in SHR function, FKBP52 has been
identified in complex with a variety of other client-Hsp90 heterocomplexes, such as those
containing kinases, aryl hydrocarbon receptor, and heat shock transcription factor to name a few.
However, many of these associations are passive and transient, and have no functional impact on
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client activity. It is likely that Hsp90 continuously samples the available pool of TPR-containing
PPIase co-chaperones and the co-chaperone that ultimately functionally interacts is dependent on
the client protein present within the complex. In addition to the Hsp90-dependent client proteins,
FKBP52 is also involved in various endocrine-independent processes (Table 1.1 and Fig. 1.3).
As previously discussed, FKBP52 belongs to a family of immunophilins, which can be targeted
by immunosuppressive molecules. This drug-immunophilin complex then docks and inhibits the
activity of calcineurin leading to immunosuppression, although FK506 binding to FKBP52 does
not inhibit calcineurin [114, 115]. Over the past decade, there has been a growing interest to
understand the role of immunophilins, including FKBP52, in the nervous system. FKBP52 is
ubiquitously expressed and especially abundant in the central nervous system. Thus, it is not
surprising that FKBP52 is involved in neurodegenerative tauopathies including Alzheimer’s
Disease (AD), Pick’s Disease, fronto-temporal dementia and Parkinsonism linked to
chromosome 17 (FTDP), and progressive supranuclear palsy [116, 117]. Tauopathies is defined
by the neuropathological characteristic of aberrant aggregation of insoluble hyperphosphorylated
microtubule-associated protein (MAP) tau within the neurons termed neurofibrillary tangles
(NFTs), which are also referred to as paired helical filaments (PHF) [118]. Recent studies have
reported that FKBP52 interacts directly with the hyperphosphorylated form of tau, which has
antagonistic effects on tubulin polymerization and microtubule assembly [119, 120]. It is worth
noting that FKBP52 regulation of microtubule assembly is likely dependent on PPIase activity,
which is in contrast to that observed with FKBP52 regulation of SHR activity. The α-Synuclein
(α-Syn) protein is a key player in the pathogenesis of Parkinson’s disease. Knockdown of
FKBP52 reduced the number of α-Syn aggregates and protected against cell death, whereas
overexpression of FKBP52 accelerated both aggregation of α-Syn and cell death [121]. Finally,
FKBP52 expression is enhanced in regenerating neurons, which stimulates neurite outgrowth and
promotes neuronal differentiation suggesting a protective or regenerative role following injury
[122, 123].
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Table 1.1 Alternative FKBP52 Interacting Proteins
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Copper (Cu) is an essential nutrient, and, as a result, cells have developed elaborated
systems for Cu storage and transport. In humans, disruption of the tightly regulated cellular Cu
homeostasis affects normal tissue development and leads to anemia, neutropenia, cancer, and
several neurodegenerative diseases including AD [124, 125]. The amyloid precursor protein
(APP) plays a central role in the development of AD through the generation of peptides called
beta-amyloid (Aβ) by proteolysis of the precursor protein. Cu contributes to the neuropathology
of AD by interacting with copper binding domain (CuBD) of APPs and Aβ peptides causing the
formation of amyloid plaques and disrupting metal ion homeostasis [126-128]. There are several
lines of evidence that have linked the protective effects of FKBP52 with intracellular Cu
homeostasis. First, FKBP52, more specifically its FK1 domain, interacts directly with APP and
Cu metallochaperone Atox1, which is a protein that delivers copper to the copper transporting
ATPases [129, 130]. Second, mutations of FKBP52 modulate the toxic effects and level of Aβ
peptides in Drosophila [130]. Third, mutations in the copper transport genes Ctr1A and Atox1,
which directly regulate intracellular copper levels, modify Aβ-induced phenotypes in Drosophila
[130]. Fourth, dietary fluctuation in the Cu levels influences the protective effects of FKBP52
on Aβ [130]. Finally, cells isolated from 52KO mice show increased levels of Cu compared to
wild type cells and overexpression of FBP52 causes efflux of copper [131].
S100A1 and S100A2 belong to the S100 family of Ca2+-binding proteins that are linked
to regulation of various intracellular processes and are often expressed in a cell- and tissuespecific fashion [132, 133]. Cellular data has linked S100A1 to neuronal cell dysfunction/death
that occurs in AD by altering APP expression, destabilizing the intracellular Ca2+ homeostasis,
and increasing sensitivity to Aβ toxicity [134]. Based on the biochemical evidence, FKBP52 is a
novel target for S100A1 and S100A2. Both proteins interact with the FKBP52 TPR domain
leading to dissociation of the immunophilin/Hsp90 complex in a Ca2+-dependent manner [42].
S100A1 and S100A2 proteins are not the only proteins that associate with and/or regulate
FKBP52 functions in a Ca2+-dependent manner.

Ca2+ homeostasis has been suggested to

regulate intracellular FKBP52 functions leading to affects on the phosphorylation of tau and
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pathology in AD. Interestingly, a Drosophila orthologue of FKBP52, termed dFKBP59, was
found to interact with the Ca2+ channel transient receptor potential-like (TRPL) protein in
photoreceptor cells and to influence Ca2+ influx [135]. Subsequent studies revealed that FKBP52
similarly interacts with a subset of rat transient receptor potential channel (TRPC) proteins that
form Ca2+ channels in the mammalian brain [136]. Although the functional importance of the
CaM-binding motifs in the C-terminal tail of FKBP52 is not known [137], these roles for
FKBP52 in multiple Ca2+-dependent functions suggest that the interaction of FKBP52 with CaM
may be yet another Ca2+-dependent mechanism by which FKBP52 could functionally affect a
wide variety of CaM-dependent physiological processes including inflammation, metabolism,
intracellular movement, smooth muscle contraction, and the immune response.
FKBP52 has also been found to interact directly with the interferon regulatory factor 4
(IRF-4) [138], which regulates gene expression in B and T lymphocytes; controls protooncogene RET by forming a complex with tyrosine kinase receptor RET51, which is involved in
the development and maintenance of the nervous system [139]; and FKBP-associated protein 48
[140], which influences proliferation of Jurkat T cells [141]. Each of these interactions was
found to be disrupted by FK506 and to target the FKBP52 PPIase domain to specific proline sites
in each partner protein. Phenotypes potentially related to these interactions have not yet been
assessed in 52KO mice. Not only does FKBP52 interact with proteins, but also directly binds
AAV DNA and regulates replication of the viral genome [95, 142]. The relevant DNA binding
site in FKBP52 has not been identified.
1.4 FKBP52 AS A NOVEL TARGET FOR PROSTATE CANCER TREATMENT
The importance of FKBP52 as a regulator for not just hormone-dependent, but also
hormone-independent diseases is becoming increasingly clear. FKBP52 is often overexpressed
in malignant hepatoma, T cell leukemia, ERα-positive breast cancer cell lines, pre-invasive and
breast cancer tissues, and hormone-dependent cancers [141, 143-147]. Furthermore, the prostate
dysgenesis observed in 52KO mice along with enhanced FKBP52 expression in several prostate
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cancer cell lines and prostate biopsy samples establish the protein as a critical regulator of ARmediated prostate development [97, 100, 148, 149]. Androgens play an important regulatory
role in the development and progression of prostate cancer (PCa) by binding to the hormone
binding pocket in the C-terminal LBD core of AR [150, 151].

The AR LBD consists

predominantly of 12 α-helices. Upon ligand binding, helix 12 is reorganized to an agonist
conformation termed activation function 2 (AF2) for co-regulator binding [152, 153] (Fig. 2c).
The primary treatment for locally advanced and metastatic PCa is androgen deprivation therapy
(ADT), in which the antiandrogens including Bicalutamide, Enzalutamide, and ARN-509 bind to
the LBD of AR [154]. These antiandrogens inhibit AR action by competing for androgen
binding and displacing helix 12 to prevent formation of a productive AF2 pocket [155]. Most
tumors respond to the treatment initially.

However, as the cancers progress they become

resistant to the therapy, in which the condition is termed castration-resistant prostate cancer
(CRPC) [156-158].

Preclinical and clinical studies suggest that acquired resistance to

conventional ADT is caused by restoration of the AR pathway by AR overexpression and
mutations, cross-talks between AR and other signaling pathways, and/or bypassing AR blockade
through up-regulation of GR [159-164]. As a result, researchers have focused their efforts on the
development of a new class of AR inhibitors termed nuclear receptor alternative-site modulators
(NRAMs) targeting alternative sites on AR and receptor regulatory proteins including receptorassociated chaperones, co-chaperones (e.g. FKBP52), co-activators (e.g. β-Catenin), and AR
inhibitors for which the binding sites are currently unknown [165]. In line with this idea, our lab
has recently identified a small molecule termed MJC13 that specifically inhibits FKBP52
regulation of AR by blocking the hormone-dependent dissociation of the AR-Hsp90-FKBP52
heterocomplex resulting in a loss of AR nuclear translocation and an inhibition of androgendependent gene expression and proliferation in prostate cancer cells [166].
FKBP52 interacts with Hsp90, and, although the specific Hsp90 contact site on the
surface of the receptor LBD has not been determined, a seven-amino acid segment located just
upstream of the receptor LBD was found to be required for stable interaction with the Hsp90 MD
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[62]. Furthermore, the fact that FKBP52 regulation has been localized to the receptor LBD and
its regulation is receptor-specific suggests that FKBP52 directly interacts with the receptor LBD
within the Hsp90 heterocomplex. Thus, we propose a model in which Hsp90 brings the FKBP52
FK1 domain, more specifically the proline-rich loop, in close proximity to the receptor LBD,
which leads to a direct interaction and regulation of receptor hormone binding and subcellular
localization. Importantly, recent studies have identified a surface region on the AR LBD that,
when mutated, displays increased functional dependence on FKBP52 and this surface overlaps
with the binding function 3 (BF3) surface (Fig. 1.2c) [166, 167].
1.4.1 AR BF3 Surface
BF3 is a recently characterized hydrophobic binding pocket on the AR LBD that is
located near, but distinct from, the AF2, which acts as a major docking site for short hydrophobic
peptide motifs featured in AR co-activators and mediates AR functional amino/carboxy (N/C)terminal interactions (Fig. 1.2c) [167-172]. The role of BF3 in vivo is currently unknown,
however, mutational and functional analyses of the surface have confirmed its role in AR activity
[173]. Small molecule docking to the BF3 surface resulted in an allosteric modification that
prevents the interactions of AF2 with co-activators [167]. In fact, in vitro studies along with
computational molecular dynamic simulations revealed a structural connection between BF3 and
AF2. A series of residues within BF3, the boundary of BF3/AF2, and AF2 are structurally
interconnected and allosterically coupled [173]. Importantly, the experiments demonstrated that
BF3 mutations function as allosteric elicitors of conformational changes in the AR LBD by
altering AF2 propensity to reorganize into hydrophobic sub-pockets that accommodate the Nterminal domain and co-activator peptides, and inhibit co-regulator binding [173]. This induced
conformation consequently may either potentiate or silence AR function. In fact, residues in the
BF3 pocket have been identified as mutational target sites for PCa and/or androgen insensitivity
syndrome

(AIS)
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Androgen
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Database:

http://androgendb.mcgill.ca/). The importance of BF3 as a regulatory surface for AR activity
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was further highlighted in recent studies by Jehle et al. [174] in which a novel hexapeptide repeat
sequence, GARRPR, was identified in the N-terminus of the co-chaperone Bag-1L that is
involved in the modulation of AR activity by binding to the BF3 pocket. Thus, the AR BF3
surface may serve as a promiscuous regulatory surface for a number of co-regulators, including
FKBP52.
1.4.2 Cross-talk between the AR and Wnt/β-Catenin Signaling Pathways in CRPC
β-catenin is a multifunctional protein that plays an important role in embryonic
development and tumorigenesis through its effect on E-cadherin-based cell adhesion and Wntdependent signal transduction [164]. It also functions as a co-activator of the AR that interacts
with the receptor in response to androgen to increase the transcriptional activity of the AR [175].
β-catenin has a central domain consists of 12 armadillo repeats and intrinsically unstructured Nand C-terminal transactivation domains [176-178]. The crystal structure of the armadillo domain
of β-catenin revealed that each of the repeat composed of three α-helices and together, adopts a
unique superhelix structure that provides a long positively charged groove for protein-protein
interaction [176-178].

It is the N-terminus combined with the first six armadillo repeats,

especially armadillos 5 and 6 that are primarily responsible for the interaction with AR LBD
[179]. It is through this specific interaction that allows β-catenin augmenting the AR activity in
a ligand-dependent manner in prostate cancer cells. Unlike other steroid receptor co-regulators,
β-catenin only selectively binds to AR, but not to other SHRs [179]. While the crystal structure
of the armadillo domain of β-catenin revealed it contains LXXLL pentapeptide that is localized
in the second helix of the armadillo repeats 1, 7, 10, and 12 [176]. However, the Leu residues in
these motifs are buried in the hydrophobic core of the armadillo repeats consequently they are
inaccessible to contribute to the interaction with AR via canonical co-regulator binding site, AF2 [176]. In addition, mutational disruption of each of five LXXLL peptide motifs in the βcatenin armadillo repeats did not disrupt neither its binding to AR nor inhibit transcriptional coactivation of transcriptional mediators/intermediary factor 2 (TIF2) [180].
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These findings

suggest β-catenin interacts with a region on AR LBD other than AF-2. In supporting with this
idea, studies have shown β-catenin synergizes with nuclear receptor co-activator glutamate
receptor-interacting protein 1 (GRIP1) via a new interaction surface differs from AF-2 on AR
LBD [181]. Interestingly, recent co-crystal structural studies of liver receptor homolog-1 (LRH1)/β-catenin revealed that the receptor utilizes a region of the LBD surface, distinct from AF-2
that was not previously implicated in protein-protein interactions with the armadillo region of βcatenin [182]. Given the high degree of structural similarity in the LBD among members of the
nuclear receptor superfamily and the fact that mutations that disrupting LRH-1/β-catenin binding
also disrupt AR/β-catenin binding [182], suggests that LRH-1 and AR share a similar β-catenin
interaction surface.
There are emergent evidence indicating the cross-talk between AR and Wnt/β-catenin
signaling pathways. As aforementioned, β-catenin binds AR directly to stimulate AR-mediated
gene transcription, and importantly, the AR gene itself is transcriptional target of β-catenin [179,
180, 183-185]. Wnt-stimulated deactivation of glycogen synthetase kinase 3β (GSK3β) and
stabilizing mutations of β-catenin cause an increased levels of nuclear β-catenin and promote AR
transcriptional activities under the conditions of androgen ablation [186, 187]. The AR signaling
has shown to repress β-catenin/T-cell factor (TCF) mediated-transcription induced by androgen
in prostate cancer cells [180, 184, 188]. The enhanced communication between AR and βcatenin has been observed in vivo models of CRPC [189]. Finally, Wnt/β-catenin signaling has
shown to be highly activated in cancer stem cells (CSCs), which are tumor-initiating cells, and
these prostate stem cells are resistant to ADT and responsible for the cancer recurrence [190].
Taken together, these data suggest a role for β-catenin interaction with the AR in the
development and progression of PCa from the hormone-dependent to the terminal castrateresistant stage.

31

1.4.3 FKBP52 and β-Catenin Act in Concert to Promote Hormone-Independent AR
Function
Given that BF-3 is the putative binding and/or regulatory site for FKBP52 with its
residues being highly conserved on the surface across the SHRs and both FKBP52 and β-catenin
are known positive regulators of AR, it is reasonable to predict that β-catenin interacts with an
AR surface that overlaps with the BF-3 (Fig. 1.3). In fact, studies have shown β-catenin binds to
a region on LRH-1 that is equivalent to the BF-3 surface on AR LBD [166, 182, 191]. Based on
this fact, our lab suggests that both FKBP52 and β-catenin might work in concert at BF-3
surface. Recently, our lab has demonstrated that they do work concomitantly; however, βcatenin requires the presence of FKBP52 to promote its interaction with AR leading to a
synergistic upregulation of the receptor activity [192]. Furthermore, the aforementioned MJC13,
which has recently been characterized by our lab of its ability to inhibit FKBP52-enhanced AR
activity via BF-3 surface in cellular models of prostate cancer, also blocks β-catenin interaction
with AR (Fig. 1.3) [192].

Taken together, FKBP52 interacts with β-catenin to promote

interaction and regulation of AR activity through BF-3 surface (Fig. 1.3). Thus, development of
inhibitors that block protein-protein interactions between the FKBP52/β-catenin/AR may be lead
to viable therapies for CRPC.
1.4.4 FKBP52 Proline-Rich Loop
The proline-rich loop that overhangs the FKBP52 PPIase catalytic pocket in the FK1
domain is required for receptor regulation and is hypothesized to serve as an interaction surface
with the receptor LBD. Our lab has recently identified several residues (F673, P723, and C806)
on the AR LBD that display increased dependence on FKBP52 (also termed FKBP52
hypersensitivity) for function when mutated. This region directly corresponds to the AR BF3
regulatory surface (Fig. 1.2c) [97, 166]. The small molecule FKBP52-specific inhibitor MJC13
binds the AR LBD, but does not compete with hormone and steroid receptor co-activator 2
(SRC-2) binding. In addition, mutations within the BF3 surface differentially affect MJC13
activity. Thus, several lines of evidence suggest that MJC13 targets the AR BF3 surface to
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inhibit regulation of AR by FKBP52.

This interaction prevents hormone-induced

AR/Hsp90/FKBP52 heterocomplex dissociation and nuclear translocation, thus effectively
blocking AR-dependent gene expression and androgen-stimulated proliferation in various human
prostate cancer cell lines [166]. Taken together, our recent findings suggest that the AR BF3
surface is a putative FKBP52 regulatory and/or interaction surface and the targeting of this
surface for the treatment of PCa is an attractive option with fewer side effects. In fact, early
preclinical studies for MJC13 suggest an excellent drug safety profile with no toxicity observed
at maximum soluble concentrations, and impressive effects on tumor growth in a 22Rv1 prostate
cancer xenograft model [193, 194]. Given the unique mechanism of action, MJC13 and other
co-chaperone targeting drugs may be able to escape the acquired resistance that is seen with
conventional ADT in subsets of patients, depending on the mechanism of resistance. MJC13 and
the N-terminal Hsp90 inhibitors lack the ability to inhibit the constitutive activity of AR splice
variants found to be up-regulated in CRPC [195]. This is not surprising given the fact that the
splice variants lack the Hsp90-binding site in the hormone binding domain. However, MJC13
does not target FKBP52 directly, but targets the putative FKBP52 regulatory site in the AR
hormone binding domain.
1.4.5 Targeting FKBP52 Proline-Rich Loop Interactions
Figure 1.4 illustrates known and predicted FKBP52 interactions and possible therapeutic
targeting strategies to disrupt FKBP52 regulation of AR. While the targeting of the FKBP52
regulatory surface on AR BF3 is a promising therapeutic strategy that allows for AR-specific
targeting, the direct targeting of FKBP52 offers numerous advantages over MJC13 that would
lead to a more potent and effective drug. First, the AR BF3 surface represents a less than ideal
drug binding site, and, as a result, the effective MJC13 concentrations in cellular assays are in
the low micromolar concentration range [166]. In contrast, the FKBP52 PPIase pocket not only
represents an ideal hydrophobic drug binding pocket, but is a known ‘druggable target’ as the
immunosuppressive drug Tacrolimus (FK506) is already FDA-approved for use in the clinic.
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Also, given the conservation within the FKBP PPIase pocket, drugs targeting the FKBP52
PPIase pocket would likely target FKBP52 and the closely related FKBP51 protein
simultaneously. While FKBP52, but not FKBP51, is largely considered the relevant steroid
hormone receptor regulator, more recent evidence suggests that both FKBP51 and FKBP52 are
positive regulators of AR in prostate cancer cells [196]. In addition, FKBP52 is a known
positive regulator of AR, GR, and PR, and the direct targeting of FKBP52 would target the
activity of all three receptors simultaneously. Increasing evidence suggests that many factors
(e.g. growth factors, cytokines, and angiogenic factors) implicated in PCa progression are targets
of the GR signaling pathway [197, 198]. In addition, recent evidence suggests that GR signaling
confers resistance to current antiandrogen treatments [159]. Furthermore, recent studies by
Cluning et al. showed that H1-H3 loop of GR LBD is not a direct interaction site for FKBP52,
however, mutations within the loop can affect FKBP52-mediated receptor activities [199]. Thus,
mechanistically, the H1-H3 loop acts as a regulatory surface that promotes conformational
changes in BF-3, which is in close proximity and allosterically affects FKBP52-mediated
receptor activities (Fig. 1.2c). While very little work has been done to characterize a role for PR
in PCa, data suggests that PR expression is elevated in metastatic diseases and that PR
antagonists are potential treatments for PCa [200, 201]. Finally, FKBP52 directly regulates
NFκB transcriptional activity [202] and inhibition of NFκB was recently demonstrated to restore
CRPC responsiveness to ADT [203]. Thus, the direct targeting of the FKBP52 proline-rich loop
with small molecules will lead to a more potent drug with the potential to simultaneously hit a
variety of targets known to have, or suspected of having, a role in PCa progression. Previous
studies demonstrated the functional importance of the FKBP52 proline-rich loop, which
establishes this site as the most attractive target site for disrupting FKBP52 interactions with the
SHRs. While this surface does not represent an ideal hydrophobic drug binding pocket, the
PPIase catalytic pocket does. In addition, the available co-crystal structure of FKBP12, a related
family member, bound to FK506 suggests that molecules docked within the PPIase pocket could
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re-orient proline-rich loop conformation leading to the disruption of interactions at this surface
(unpublished observations).
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Figure 1.4: FKBP52-Receptor Interactions and Therapeutic Targeting Strategies
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Fig. 1.4: FKPB52-Receptor Interaction and Therapeutic Targeting Strategies. Both known
(solid arrow) and predicted (dashed arrow) FKBP52-Hsp90-receptor interactions are illustrated
in addition to possible strategies for therapeutically disrupting chaperone/co-chaperone
regulation of AR-mediated transcription for the treatment of prostate cancer. FKBP52 is a known
positive regulator of AR function that associates with the EEVD motif in the C-terminus of
Hsp90 by way of a TPR domain. In addition, the FKBP52 FK1 domain, the PPIase pocket, and
the proline-rich loop in particular, comprise a functionally important interaction surface that is
predicted to interact with the AR hormone binding domain. The prevailing hypothesis is that
Hsp90 brings FKBP52 in close proximity to the receptor allowing the FKBP52 FK1 domain to
directly contact the receptor hormone binding domain. Our recent data suggest that this contact
site is the AR BF3 surface. As detailed, several drug classes already exist for the inhibition of
Hsp90 (geldanamycin and derivatives) and FKBP52 (FK506 also called Tacrolimus).
Geldanamycin is currently in phase III clinical trials for the treatment of various cancers, but has
proven ineffective in prostate cancer. Tacrolimus is currently used clinically to suppress the
immune system during organ transplantation, and the immunosuppressive effects would be
undesirable in a prostate cancer drug. However, the success of Tacrolimus in the clinic indicates
that FKBP52 is a “druggable” protein. Targeting of the FKBP52 TPR domain, which would
theoretically disrupt FKBP52 interactions with Hsp90, is a possible approach. However, the
TPR motif is highly conserved and any molecule that targets the FKBP52 TPR would also likely
target a large number of other TPR proteins. The targeting of the proposed FKBP52/β-catenin
binding site on the AR hormone binding domain is also an attractive option. This approach is
represented by the compound termed MJC13 and derivatives that were recently developed by our
laboratory. Directly targeting the FKBP52 proline-rich loop represents the most promising
approach as FKBP52 is a “druggable” protein and the proline-rich loop has been found to be
critical for FKBP52 regulation of AR activity.
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1.5 DISSERTATION PROJECT RATIONALE AND HYPOTHESIS
The Hsp90-associated FKBP52 co-chaperone has become increasingly associated with
aberrant SHR signaling in diseases. FKBP52 is a TPR-containing co-chaperone that plays a
critical role in the chaperone-dependent folding of SHRs to their functionally mature
conformations that are competent for hormone binding. Given the functional roles of FKBP52 in
receptor-specific phenotypes, and its direct participation in the aberrant AR hyperactivity
observed in PCa, FKBP52 has emerged as a novel therapeutic target with the potential to treat
CRPC; thereby filling a major unmet need in PCa treatment. We hypothesized that specific small
molecules targeting the FKBP52 PPIase pocket will disrupt FKBP52 proline-rich loop
interactions leading to the effective inhibition of AR, GR, and PR signaling, prostate cancer cell
proliferation, and attenuate the expression and/or secretion of prostate cancer biomarkers. In
addition to PCa, the therapeutic targeting of FKBP52 proline-rich loop interactions represents an
attractive treatment option for a number of diseases associated with the AR, GR, and PR
signaling pathways including benign prostatic hyperplasia, obesity/metabolic syndrome, stress
and depression, and Cushing’s syndrome. Furthermore, drugs targeting FKBP52 regulation of
SHR activity may have utility as male and/or female contraceptives.
1.6 DISSERTATION GOALS
The overall goal of the project was to develop first-in-class drugs targeting the FKBP52
PPIase pocket for the disruption of proline-rich loop interactions with AR for the treatment of
PCa. The objective was addressed by the following studies:
1. Identification of novel FKBP52-specific molecules that inhibit FKBP52enhanced receptor function using structure-based virtual screening.
2. Molecular and cellular evaluations of the lead compound in various prostate
cancer cellular models.
3. Verification of the lead compound drug target site.
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4. Solution formulation development of GMC1 and perform preclinical evaluations
of the lead compound in murine prostate cancer model.
The data ultimately gleaned from these studies will establish “indirect AR targeting”
through the inhibition of FKBP52 as a promising strategy in combating PCa with limited offtarget effects. Furthermore, it may provide insights into novel roles for the FKBPs in PCa and
other hormone-dependent diseases, and provide a better understanding of how the co-chaperone
regulates receptors from a structural and mechanistic point of view.
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CHAPTER 2: IDENTIFICATION OF SMALL MOLECULE INHIBITORS
SELECTIVELY TARGETING FKBP52 PROLINE-RICH LOOP
INTERACTIONS USING STRUCTURE-BASED METHODOLOGY
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2.1 RATIONALE
As aforementioned, FKBP52 is an Hsp90-associated co-chaperone and acts as a positive
regulator of a small subset of Hsp90 client proteins including AR, GR, and PR. The cochaperone potentiates these receptor signaling pathways via interactions between the proline-rich
loop overhanging the PPIase catalytic pocket located in the FK1 domain and the AR BF3 surface
on the LBD. It is important to note that the structural integrity of the loop, not the PPIase
enzymatic activity, is functionally crucial for the regulation of receptor activity. There are
several lines of evidence that demonstrate direct targeting of FKBP52 for the disruption of
proline-rich loop interactions with LBD can serve as a highly specific therapeutic strategy to
inhibit FKBP52-mediated Hsp90-dependent and independent diseases including PCa.

First,

fkbp52-deficient mice display phenotypes related to defective AR, GR, and PR signaling.
Second, prostate cancer cells have been shown to bypass AR-dependence through the GR
signaling pathway [159, 204-207]. Third, studies have demonstrated PR expression is often
elevated during the progression of metastatic and recurrent prostatic adenocarcinoma and PR
antagonists have potential in treating PCa [200, 201]. Lastly, FKBP52 has been proven to be a
“druggable” target, which means it can be targeted without significant off-target effects and
circumvent undesirable side effects and resistance mechanisms associated with current ADT. In
our attempts to discover new small molecules inhibitors that could specifically target the prolinerich loop, we performed a structure-based in silico screen of a library of commercially available
molecules. Unfortunately, the proline-rich loop interaction surface does not represent an ideal
hydrophobic drug binding site, but the highly conserved PPIase catalytic pocket does, which
provides a foundation for structure-based drug design. In addition, the co-crystal structure of
FKBP12, a related family member, bound to the FK506 ligand suggests that molecules docked
within the PPIase pocket could re-orient proline-rich loop conformation leading to the disruption
of the FKBP52/receptor interaction surface. Therefore, in this study, we targeted the FKBP52
PPIase catalytic pocket with small molecules to disrupt the proline-rich loop interactions leading
to effective inhibition of FKBP52-regulated AR activities.
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2.2 MATERIALS AND METHODS
2.2.1 Protein and Ligand Preparation
The crystal structures were prepared using the Protein Preparation Wizard implemented
in Maestro 9.3 (Schrödinger, LLC) [208].

The hydrogens were added, bond orders were

assigned, and missing side chains for some residues were added using Optimized Potential for
Liquid Simulations (OPLS)-2005 force field, and the receptor grid was defined using a 20 Å box
centered on the crystallographic ligand. A library of 3 million commercially available molecules
from the ZINC database [209] was imported into Molecular Operating Environment (MOE)
2011. All the molecules were protonated/deprotonated by a washing process, added partial
charges and minimized with the Merck Molecular Force Field (MMFF) 94x force field to a
gradient of 0.0001 kcal/mol Å. Duplicate compounds in the database were removed using the db
_unique.svl module from the MOE.
2.2.2 Molecular Docking-Based In Silico Screening of Potential FKBP52 PPIase Pocket
Inhibitors
Two docking programs, Glide and eHiTs, were used for virtual high-throughput
screening implemented on a Sun Grid Engine Cluster [210, 211]. The Glide SP mode was
initially used for filtering out compounds with low docking scores (SP < -5.5). The active
binding site was defined from the coordination of crystallographic ligand (PDB code: 4LAX)
[92] using the default settings.

To avoid any bias in docking programs, compounds with

favorable Glide scores were subsequently docked by eHiTs, and compounds with eHiTs score
higher than cutoff value (-1) were removed. The root-mean-square deviation (RMSD) of the
docked poses generated by Glide and eHiTs were then calculated to keep compounds with
consistent docked poses.

Compounds with high RMSD values (> 2.5) were removed.

Subsequently, the glide poses was re-scored by multiple scoring functions (glide SP, XP, Xscore,
Pki, and LonDonDG). Depending upon the scores, each molecule received a vote value of “1”
for every top 10% appearance by ranking of each score, which then generated a consensus voting
for the selection. Following the ranking of the consensus voting value, top virtual hits were
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visualized and compounds with favorable interactions were selected. All tested compounds were
then purchased from commercial vendors for empirical testing.
2.2.3 Cell Culture
MDA-kb2 cells were purchased from the American Type Culture Collection (ATCC®
CRL-2713™) and express firefly luciferase under control of the MMTV promoter that contains
response elements for both AR and GR. They were maintained in Hyclone™ Leibovitz’s L-15
Medium (Thermo Scientific) supplemented with 10% fetal bovine serum (FBS, Atlas) at 37°C
without supplemental CO2.

Mouse embryonic fibroblast cells from homozygous FKBP52

knockout embryos (52KO MEF) were generated as previously described [98].

They were

maintained in Hyclone™ Minimal Essential Media/Earle’s Balanced Salt Solution (MEM/EBSS)
containing 2 mM L-glutamine (Thermo Scientific) supplemented with 10% FBS at 37°C with
supplemental 5% CO2.
2.2.4 Mammalian Cell-Based Luciferase Reporter Assays
MDA-kb2 cells were used for the Bright-Glo™ luciferase assay system (Promega) to
screen the hit compounds. The cells were plated at 4 x 104 cells per well in 96-well luminometer
plates in 100 µl of Hyclone™ Leibovitz’s L-15 Medium with 10% FBS and allow to attach at
37°C without supplemental CO2. When cells were attached, they were washed three times and
replaced with 100 µl of medium containing 10% charcoal-stripped FBS (CS-FBS; Corning) at
37°C without supplemental CO2. The next day, the medium was replaced with 100 µl of fresh
medium containing 10% CS-FBS per well dosing with ethanol (EtOH) only (agonist vehicle
control), dimethyl sulfoxide (DMSO) only (hit compound vehicle control), DMSO + EtOH
(negative control), DMSO plus the agonist (dihydrotestosterone, DHT, at 200 pM, which is an
EC50 for the hormone in this cell line; positive control), or the agonist plus a hit compound at a
concentration range of 10 nM, 100 nM, 1 µM, 10 µM, and 100 µM, incubated for 16-20 h at
37°C without supplemental CO2. The final EtOH concentration in each well did not exceed 1%
nor did the DMSO. Then the AR luciferase reporter assay was performed and activity measured
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according to manufacturer’s instructions. Relative light units (RLU) per well were determined
using a microplate luminometer (Luminoskan Ascent, Thermo Labsystems).

Individual

compound at each concentration was assayed independently at least 3 times with duplicate wells
per each replicate assay.
52KO MEFs were used to assess FKBP52-regulated AR-mediated luciferase activity.
The cells were seeded at 2 x 105 cells per well in 6-well tissue culture-treated plates at
approximately 80% confluency in 1.5 mL of Hyclone™ MEM/EBSS containing 2 mM Lglutamine with 10% FBS and allowed to attach at 37°C with supplemental 5% CO2. Once the
cells were attached, medium was removed and replaced with 1 mL of Hyclone™ MEM/EBSS
containing 2 mM L-glutamine without 10% FBS plus 500 µL of transfection mixture after
washed 3 times with the medium and allowed to incubate at 37°C with supplemental 5% CO2 for
4-6 h. The plasmids were transfected using Lipofectamine® 2000 Reagent (Invitrogen™, Thermo
Scientific) according to the manufacture protocol with a DNA to Lipofectamine® ratio of 1:3 in
Hyclone™ MEM/EBSS containing 2 mM L-glutamine without 10% FBS. The plasmids used
for the experiments were as follows: a constitutive β-galactosidase expression plasmid (50 ng per
well; transfection control), a hormone-responsive firefly luciferase reporter (400 ng per well), a
mammalian expression vector (pCI-Neo; Promega) expressing AR (800 ng per well), an empty
pCI-Neo (800 ng per well; negative control), and a pCI-Neo expressing FKBP52 (800 ng per
well). After the transfection incubation, the medium was removed and replaced with 1.5 mL of
Hyclone™ MEM/EBSS containing 2 mM L-glutamine supplemented with 10% CS-FBS. 24 h
after the transfection, cells were treated with indicated inhibitor concentrations for 30 min
followed by the treatment with DHT in fresh 1.5 mL of Hyclone™ MEM/EBSS containing 2 mM
L-glutamine supplemented with 10% CS-FBS. Stock inhibitors and DHT concentrations were
prepared in DMSO and EtOH, respectively. The DHT concentrations used in the experiment
corresponded to the pre-determined EC50 at each experimental condition; the mammalian
expression vector control group at 1 nM and mammalian expression vector expressing FKBP52
group at 10 pM. In no case did the EtOH and DMSO concentrations exceeded 0.1% and 1%,
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respectively. After 16-18 h of the treatment, the cells were washed with Hyclone™ phosphate
buffered saline (PBS; Thermo Scientific) at room temperature, and then 150 µL lysis buffer (10
mL of M-PER™ Mammalian Protein Extraction Reagent plus 100 µL of Halt™ Protease Inhibitor
Cocktail, ethylenediaminetetraacetic acid (EDTA)-free; Thermo Scientific) were added per well
incubated for 10 min at room temperature on a plate shaker. The cell lysates were collected by
centrifugation at 15,000 rpm at 4°C for 20 min. Luciferase expression was quantified using
Luciferase Assay System (Promega) with 40 µL of cell lysate with 100 µL of the reagent per
well in an opaque 96-well plate and RLU per well were determined immediately using Synergy 2
Multi-Mode Microplate Reader (BioTek). β-galactosidase expression was quantified using the
Tropix® Gal-Screen™ assay system (Applied Biosystems) with 10 µL of cell lysate with 100 µL
of the reagent per well in an opaque 96-well plate according to the manufacturer protocol,
incubated for 2 h in the dark at room temperature, then RLU were measured using Synergy 2.
Ar-dependent reporter expressions were normalized against transfection efficiencies by dividing
luciferase RLU by the β-galactosidase RLU.
2.2.5 Statistical Analysis
All data are presented as mean ± standard deviation and is the average of triplicate
biological samples in a single experiment.

Each experiment was repeated at least three

independent times. The graphs presented represent the average from all experiments. GraphPad
PRISM software (GradphPad Inc.) was used for generate the graphs.
2.3 RESULTS
2.3.1 Identification of Key Interaction Sites on the FKBP52 PPIase Pocket
As aforementioned, the FKBP52 proline-rich loop is not a druggable hydrophobic
binding site, but the PPIase catalytic pocket underneath the loop is. Thus, we hypothesized that
specifc small molecule interactions within the PPIase pocket would reorient proline-rich loop
conformation leading to the disruption of the receptor interaction surface. The PPIase catalytic
pocket in the FK1 domain of FKBP52 is a very hydrophobic surface with only few polar
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residues. The co-crystal structure of FKBP52 FK1 domain with FK506 bound in the PPIase
pocket was not solved at the beginning of this study. Thus, FKBP12 in complex with FK506
was used as a reference. FK506 binding to FKBP12 shows three key hydrogen bond interactions
between the ligand and Asp37, Ile56, and Tyr 82, which correspond to Asp68, Ile87, and Tyr113
in FKBP52 (Fig. 2.1). These polar residues were predicted to be critical in anchoring possible
binding of small molecules.
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Figure 2.1: Structure-Based Design of Direct FKBP52 Targeting Small Molecule Inhibitors
Left panel depicts the 3D image of co-crystal structure of FKBP52 with FK506 in the PPIase site
in FK1 domain (PDB code: 4LAX). Right panel illustrates the polar residues Asp68, Ile87, and
Tyr113 form key interactions between the ligand and FKBP52 PPIase pocket. The FK1 domain
and FK506 are in cartoon and stick representation, respectively. The red dashed lines indicate
hydrogen bonding.
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2.3.2 In Silico Identification of Hit Compounds Targeting the FKBP52 PPIase Catalytic
Pocket
The ZINC molecular database containing approximately 3 million lead-like compounds
was processed against the identified binding site on the PPIase catalytic pocket through a virtual
screening pipeline. They were subjected to two docking programs, Glide and eHiTs, using SP <
-5.5 and eHiTs score < -1 as cutoffs resulting 508,213 molecules left. Subsequently, RMSD
values were calculated between the docked poses from these programs, and only molecules
(8,072 molecules) with consistent pose were retained (0 < RMSD < 2.5). Finally, based on the
consensus voting values, top virtual hits were visualized and those did not retain the key
interactions were eliminated resulting in 40 selected hit compounds, which all maintain the
hydrogen bond interactions with Asp68, Ile87, and Tyr113, for functional screening.
2.3.3 In Vitro Evaluation and Identification of a Small Molecule Inhibitor that Targets
FKBP52-Specific Regulation of AR Function
The MDA-kb2 cell line is a breast cancer cell line that contains stable AR and GRresponsive luciferase reporter genes which means any compounds that act through either AR or
GR-mediated signaling can be detected [212]. Additionally, this cell line was derived from a
single stable clone, which does not require transfection of the receptors, and is relatively easy to
culture and maintain. Thus, it serves as an inexpensive tool for screening drug molecules with
minimal inter and intra-assay variability. The 40 hit molecules out of initial 3 million lead-like
compounds from the ZINC library were commercially purchased and assessed for their ability to
inhibit AR-mediated luciferase reporter expression in MDA-kb2 cells with a range of
concentrations. Any molecules that displayed an increased potency with a full inhibitory curve
in the assay were further assessed for inhibitory effects on FKBP52-specific regulation of AR
activity in 52KO MEFs. This cell line was used because they are the only existing cells that
could provide a true FKBP52-negative background for evaluating FKBP-specific effects of the
drug candidates.
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The selected molecules that displayed inhibitory effects on AR-mediated luciferase
expression in MDA-kb2 cells were initially subjected to testing for the ability to specifically
inhibit FKBP52-regulated receptor activity at a single high dose of 100 µM. Any molecules that
demonstrated FKBP52-specific inhibitory effects on AR function at a single high dose were
subsequently assessed at a range of concentrations to determine the IC50 values. It is important
to note that the hormone-induced receptor activity requires a very high hormone concentration in
the absence of FKBP52, therefore the receptor activity in the presence and absence of the cochaperone was assessed at a low and high hormone concentrations at 10 pM and 1 nM,
respectively. The AR activity in the absence of FKBP52 served both as controls for FKBP52specificity and general cellular toxicity.
GMC1 was our resulting lead molecule that displayed the most potent FKBP52-specific
inhibition of AR activity (Fig. 2.2). It showed an increased potency with maximal inhibition of
AR activity at 100 µM and an IC50 value of 8.83 µM (Fig. 2.2a). GMC1 also demonstrated a
significant reduction of FKBP52-regulated AR-mediated luciferase expression at 100 µM (data
now shown) and displayed a full inhibitory curve with an IC50 value at 0.6576 µM (Fig. 2.2b).
Fig 2.2c depicts the molecular docking of GMC1 into the FKBP52 PPIase site with key polar
residues Asp68, Ile87, and Tyr113.
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Figure 2.2: GMC1 Inhibits FKBP52-Specific AR-Mediated Activity
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Fig. 2.2: GMC1 Inhibits FKBP52-Specific AR-Mediated Activity.

(a) MDA-kb2 cells

expressing stably transfected AR- and GR-responsive luciferase reporter genes were treated with
200 pM DHT and a range of GMC1 concentrations (0, 0.01, 0.1, 1, 10, and 100 µM) for 16-20 h
for testing AR-dependent activity. The graph depicts an average of three independent receptormediated luciferase reporter experiments.

(b) The graphs demonstrated an average of three

independent luciferase reporter assays in 52KO MEF cells in the presence and absence of
FKBP52 treated with 10 pM DHT and 1 nM DHT, respectively, and a range of
GMC1concentrations (0, 0.001, 0.01, 0.05, 0.1, 0.5, 1, 10, 100 µM) for the assessment of
FKBP52-specific AR-mediated activity. Each IC50 value is represented as means ± s.d. of an
average of three independent experiments. (c) The ZINC database with 3 million lead-like
compounds was processed through the in silico screening pipeline and 40 molecules were
selected for functional testing. The left panel of (c) depicts the docked pose of identified lead
molecule GMC1 (cyan) in the FKBP52 PPIase site with key residues labeled. The right panel of
(c) shows the GMC1-FKBP52 interactions in a 2D diagram.
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2.4 DISCUSSION
In this study, we showed that the FKBP52 PPIase catalytic pocket represents a viable
drug target for small molecules using structure-based virtual screening methods. We employed
FKBP12 in complex with FK506 as a reference, which was later confirmed with the resolved cocrystal structure of FKBP52 FK1-FK506, and identified a predicted target site within the PPIase
pocket containing Asp68, Ile87, and Tyr113 as three key residues forming hydrogen bonding
with ligands. Using the FKBP52 PPIase as a target site for the in silico screen, we obtained 40
structurally diverse hit compounds from 3 million commercially available chemical structures.
We evaluated the effect of these selected hit compounds on AR-mediated reporter activity using
MDA-kb2 cells. From that screen, we selected compounds that displayed a full inhibitory curve
against hormone-induced receptor activity.

In order to determine whether the observed

inhibition of AR signaling in MDA-kb2 cells was due to FKBP52-specific effects, the molecules
were then tested in 52KO MEFs. GMC1 was the resulting lead molecule that demonstrated
potent FKBP52-specific AR-regulated signaling with an IC50 value at high nanomolar
concentrations. Interestingly, GMC1, without optimization by structure-activity relationship
(SAR) analysis, inhibited AR activity at a concentration comparable to the AR BF3-binding
drug, MJC13, which was developed and optimized previously by our lab. This suggests that
disruption of the FKBP52 proline-rich loop interaction with AR is a more potent drug target than
targeting the LBD surface. Thus, GMC1 represents a novel and powerful first-in-class drug for
directly targeting FKBP52 for the disruption of steroid hormone receptor activity.
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CHAPTER 3: IN VITRO EVALUTION AND CHARACTERIZATION OF
GMC1 IN PROSTATE CANCER CELLULAR MODELS
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3.1 RATIONALE
The androgen and AR are central drivers of PCa development and progression as
evidenced by the life prolonging effects of ADT using antiandrogens.

Antiandrogens are

compounds that compete with endogenous androgens for AR, a hormone activated transcription
factor, and thereby blocking the biological effects of testosterone and DHT by inducing
conformational change of the receptor leading to the inhibition of AR-dependent transcription.
Unfortunately, a majority of patients treated with antiandrogens will eventually develop CRPC
within 2 years of initial treatment and it is currently incurable [156, 213]. Mounting evidence
has suggested that therapeutic failure and castration-resistant progression of the disease are due
to resurgence of AR activity [214, 215]. Mechanisms of resistance include AR mutation and
amplification, increased intracellular testosterone production, altered co-regulator expression,
alternative activation through signaling cross-talk, and elevated expression of constitutively
active AR splice variants. [216-221]. In some cases, the AR is bypassed by the activation of
alternative signaling pathways such as GR [159, 204-207]. Thus, treatments for CRPC represent
a huge unmet clinical need.
It is important to note that AR activity is necessary but not sufficient for the emergence
and survival of PCa. Therefore, therapeutic strategies that down-regulate AR activity can be
complemented by alternative strategies that target mechanisms promoting cancer metastasis.
MJC13 is an excellent example that a first-in-class drug that targets an AR regulatory surface
other than LBD is a viable approach to inhibit AR action in early hormone-dependent PCa as
well as in CRPC. The compound acts as a surface-directed antagonist inhibiting FKBP52enhanced AR activity by binding to the AR BF3 surface. BF3 is a novel AR surface that is
required for receptor activity; it is often subject to natural mutation in patients with PCa and in
AIS. A line of evidence has suggested BF3 constitutes a multifunctional interaction surface for
proteins like FKBP52, β-catenin, and Bag-1L [167, 173, 192]. MJC13 has demonstrated effects
not only in promoting arrest of the AR-FKBP52-Hsp90 complex in the cytoplasm, reducing rates
of AR nuclear translocation, and inhibiting DHT-dependent transcriptional activity; but also in
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blocking SRC2 and β-catenin interactions with the receptor [192, 222]. Additionally, MJC13
displays inhibitory effects on androgen responsive genes indistinguishable from classic AR
antagonists [222]. Furthermore, it demonstrates impressive inhibitory effects on tumor growth in
a prostate cancer xenograft model [223]. Thus, a new class of NRAMs that targets novel
regulatory surfaces on AR presents as an attractive therapeutic option.
As aforementioned, targeting AR regulatory proteins including receptor-associated cochaperones also represents a compelling therapeutic opportunity. FKBP52 is such a candidate
that we believe would lead to a more potent and effective drug in treating early hormonedependent PCa as well as CRPC compared to MJC13 and current FDA-approved antiandrogens.
As discussed in Chapter 2, we have demonstrated that the FKBP52 PPIase catalytic pocket is an
ideal hydrophobic drug-binding site and targeting it disrupts the architectural integrity of the
overhanging proline-rich loop, which is an important interaction surface between the cochaperone and its specific Hsp90 client proteins including AR, GR, and PR. Given the fact that a
combined chemotherapy and GR agonist is a standard treatment in CRPC patients and PR
expression is often elevated during the progression of metastatic and recurrent prostatic
adenocarcinoma, we believe that a molecule targeting FKBP52 directly would have multiple
effects on a variety of targets known to have, or suspected of having, a role in PCa. The
resulting initial lead molecule termed GMC1 from Chapter 2 has demonstrated a potent
inhibitory effect on FKBP52-specific AR-regulated activity with an IC50 value that was
comparable to MJC13, which has already been structurally optimized. In this study, we planned
to demonstrate that GMC1 inhibits both FKBP52-regulated GR and PR activities and generate
proof-of-concept data in various prostate cancer cellular models via detailed in vitro evaluations
to establish FKBP52 PPIase targeting GMC1 as an effective therapy for PCa.
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3.2 MATERIALS AND METHODS
3.2.1 Cell Culture
MDA-kb2 and 52KO MEF were acquired and maintained as described in Chapter 2.2.3.
T47D-KBluc (CRL-2865™), 22Rv1 (CRL-2505™), and PC3 (CRL-1435™) were purchased from
ATCC. T47D-Bluc cells were generated by stably transfecting T47D human breast cancer cells,
which naturally express ERα and ERβ, with pGL2.TATA.Inr.luc.neo that contains three estrogen
responsive elements (ERE) upstream of a luciferase reporter gene. They were selected for
responsiveness to 17β-estradiol (E2) and were used to screen compounds for estrogenic or antiestrogenic activity. 22Rv1 is a human prostate carcinoma epithelial cell line derived from a
xenograft that was serially propagated in mice after castration-induced regression and relapse of
the parental, androgen-dependent CWR22 xenograft [224]. During the progression to androgen
independence, an in-frame tandem duplication of exon 3 that encodes the second zinc finger of
the AR DNA-binding domain (DBD) occurred, resulting in a constitutively active truncated form
of AR lacking the C-terminal LBD [225]. As a result, 22Rv1 cells display both androgenresponsive and androgen-insensitive characteristics. PC3 is an androgen-independent prostate
cancer cell line that was derived from a grade IV prostatic adenocarcinoma that metastasized to
bone and is negative in AR expression. LNCaP were both purchased from ATCC (CRL-1740™)
and generously provided by Dr. Donald Tindall (Mayo Clinic, Rochester, MN). The cell line
was derived from a metastatic site of prostate carcinoma and characterized with a T877A
mutation in AR LBD [226, 227]. T47D-BLuc and LNCaP were maintained in Hyclone™ RPMI
1640 containing 25mM HEPES and L-glutamine (Thermo Scientific) supplemented with 10%
FBS.

22Rv1 were cultured in Hyclone™ RPMI 1640 containing 25mM HEPES and L-

glutamine supplemented with Hyclone™ 1% sodium pyruvate (Thermo Scientific), Hyclone™ 1%
MEM-nonessential amino acids (MEM-NEAA, Thermo Scientific), and 10% FBS. PC3 were
maintained in Gibco® Ham’s F12 medium containing L-glutamine supplemented with 5% FBS
(Thermo Scientific). T47D-KBluc, LNCaP, 22Rv1, and PC3 were all cultured at 37°C in a
humidified environment of 5% CO2.
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3.2.2 Transient Transfections and Luciferase Reporter Assays
The MDA-kb2 and 52KO MEF luciferase reporter assays were performed as previously
described in Chapter 2.2.4 with a few modifications.

A GR agonist, dexamethasone (DEX; 50

nM), was used to induce GR-mediated luciferase expression in MDA-kb2. The 800 ng per well
of mammalian expression vector plasmid (pCI-Neo; Promega) expressing human GR or PR
instead of AR were used in the transfection cocktail to determine FKBP52-regulated GR and PRmediated activities. The deoxycorticosterone (DOC) and progesterone (P4) concentrations used
in the experiment corresponded to the pre-determined EC50 values at each experimental
condition; the 500 nM DOC and 2.5 nM P4 were used in mammalian expression vector control
groups and 50 nM DOC and 100 pM P4 were used in mammalian expression vector expressing
FKBP52 groups.
LNCaP cells were used to assess GMC1 effects on AR-dependent prostate specific
antigen (PSA) luciferase activity. The cells were seeded at 1.5 x 105 cells per well in 24-well
plates in 500 µL of standard growth media as described in section 3.2.1. The following day, the
PSA-Enhancer/Promoter Luciferase (EPLuc) plasmid (0.5 µg per well) was transfected using
Lipofectamine® 2000 Reagent with Opti-MEM® reduced serum media containing L-glutamine
(Thermo Scientific). The PSA-EPLuc plasmid was constructed as previously described [228]. A
621-bp fragment of PSA minimal promoter (_610 to _11 nt) was amplified by PCR and cloned at
the SmaI and XhoI sites of pGL3-basic luciferase vector (Promega), after which an 823-bp
upstream enhancer fragment (_4758 to _3935 bp) containing the _4.1/_3.9 kb PSA core enhancer
region was obtained by PCR and inserted upstream of the PSA promoter at SacI and SmaI sites
resulting in a PSA-EPLuc reporter construct. After 6 h of incubation with transfection mixture,
the Opti-MEM® reduced serum media containing L-glutamine was replaced with standard
growth media as described previously with the addition of DMSO (inhibitor vehicle control;
positive control), Bicalutamide, MDV3100, MJC13, or GMC1 at indicated concentration range,
incubated for 24 h at 37°C with supplemental 5% CO2. The final DMSO concentration in each
well did not exceed 0.1%. The cells were harvested and lysed with 100 µL per well of Reporter
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Lysis Buffer (Promega). Then the PSA luciferase reporter activity was performed and measured
using the Luciferase Assay System (Promega) according to manufacturer’s instructions. RLU
per well were determined using a Perkin Elmer 420 multi-label counter. Results are represented
as relative luciferase activities.
T47D-KBluc cells were used for the Bright-Glo™ luciferase assay system to determine
GMC1 effects on ER-regulated activity. The cells were plated at 3 x 104 cells per well in 96well plates in 100 µl of Gibco® RPMI Medium 1640 containing L-glutamine without phenol red
(Life Technologies™) supplemented with 10% CS-FBS at 37°C in a humidified environment of
5% CO2. The medium was replaced the next day with 100 µl of fresh medium without phenol
red containing 10% CS-FBS per well dosing with EtOH only (agonist vehicle control), DMSO
only (GMC1 vehicle control), DMSO + EtOH (negative control), DMSO plus the agonist (E2, at
10 pM, which is an EC50 for the hormone in this cell line; positive control), or the agonist plus
GMC1 at a concentration range of 1 nM, 10 nM, 50 nM, 100 nM, 500 nM, 1 µM, 10 µM, and
100 µM, incubated for 16-20 h at 37°C with supplemental 5% CO2.

The final EtOH

concentration in each well did not exceed 1% nor did the DMSO. The ER luciferase reporter
activity was measured according to the manufacturer’s instructions.

RLU per well were

determined using a Luminoskan Ascent microplate luminometer. GMC1 at each concentration
was assayed independently 3 times (3 replicate assays) with duplicate wells per each replicate
assay.
3.2.3 Western Immunoblot Analysis
LNCaP and 22Rv1 cells were used to assess GMC1 effects in AR and AR-dependent
gene expression. The cells were plated at a density of 5 x 105 cells per well in 12-well plates in 1
mL of respective standard growth media as detailed in section 3.2.1 and incubated at 37°C with
supplemental 5% CO2 and allowed to attach for 48 h. The media were removed and cells were
then washed three times and replaced with fresh 1 mL of respective growth media modified by
replacement of 10% FBS with 10% CS-FBS at 37°C with supplemental 5% CO2. After 48 h, the
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cells were treated with DMSO + EtOH (negative control), DMSO + agonist (DHT, 50 nM for
LNCaP and 1 nM for 22Rv1, positive control), or the agonist with a range of GMC1
concentrations (100 nM, 500 nM, 1 µM, 10 µM, 25 µM, 50 µM, 75 µM, and 100 µM) for 24 h.
The final EtOH and DMSO concentrations in each well did not exceed 0.1% and 1 %,
respectively. The cells were lysed and collected as described in Chapter 2.2.4. The protein
concentration was quantitated with Peirce™ Coomassie (Bradford) Protein Assay kit (Thermo
Scientific). Proteins (60 µg of lysate) were separated by Criterion™ TGX™ 10-20% Precast Gels
(Bio-Rad) and transferred to Immobilon-P polyvinylidene difluoride membranes (PVDF;
Millipore). Membranes were blocked for 30 min with 5% nonfat dry milk in Tris-buffered saline
containing 0.1% Tween 20 (TBST). The primary mouse monoclonal antibodies used for the
experiments were as follows: anti-FKBP51 Hi51C (1:5000; developed in the laboratory of Dr.
David Smith and available from our laboratory) and anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, 1:3000; loading control; Santa Cruz). The primary rabbit antibodies
used for the experiments were as the following: polyclonal anti-AR N-20 (1:1000; Santa Cruz)
and monoclonal anti-PSA/KLK3 D11E1 XP® (1:500; Cell Signaling). Primary antibodies were
diluted in blocking buffer and incubated with the membranes for 2 h with gently shaking at room
temperature with the exception of PSA/KLK3 mAb; it was diluted in 5% w/v bovine serum
albumin (BSA; Sigma)/1X TBST and incubated with the membranes at 4°C with gentle shaking,
overnight.

The membranes were washed 5 times with TBST, 5 min per wash with shaking and

subsequently incubated with a 1:5000 dilution of the appropriate alkaline phosphatase (AP)conjugated goat anti-mouse and goat anti-rabbit antibodies diluted with blocking buffer and
incubated with the membranes for 1 h at room temperature with gentle shaking. After washing 5
times with TBST and 2 times with TBS, 5 min per wash, the membranes were developed with
Immun-Star™ AP substrate (Bio-Rad) and exposed to CL-XPosure Film (Thermo Scientific).
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3.2.4 Prostate-Specific Antigen (PSA) ELISA Assay
LNCaP and 22Rv1 cells were used for the Human PSA ELISA Kit (Alpha Diagnostic
International, ADI) to quantify secreted PSA in the media. The cells were plated at a density of
2 x 105 cells per well in 12-well plates in 1 mL of respective standard growth media as detailed
in section 3.2.1 incubated at 37°C with supplemental 5% CO2. When cells were attached, they
were washed three times and replaced with 1 mL of respective growth media modified by
replacement of 10% FBS with 10% CS-FBS at 37°C with supplemental 5% CO2. After 48 h, the
cells were treated with DMSO + EtOH (negative control), DMSO + agonist (DHT, 50 nM for
LNCaP and 1 nM for 22Rv1, positive control), or the agonist with a range of GMC1
concentrations (1 µM, 25 µM, 50 µM, 75 µM, and 100 µM) for 24 h. For evaluating basal and
hormone-induced PSA secretion in 22Rv1 cells, the aforementioned experimental conditions
were used with the exception of GMC1 concentrations; the hormone-induced activity was only
tested at a single high dose (100 µM).

Supernatant were collected and the assays were

performed according to manufacturer’s instructions.

25 µL of standards, controls, and

supernatant samples were added into appropriate wells containing 100 µL of assay buffer in
duplicate, covered, and incubated on a plate shaker (approximately at 200 rpm) for 60 min at
room temperature. The wells were washed 3 times with 300 µL of 1X wash buffer followed by
the addition of 100 µL of Ab-enzyme conjugate into each well, mixed gently for 10 secs,
covered, and incubated the plate on a plate shaker (approximately at 200 rpm) for 30 min at room
temperature. The wells were then washed 3 times with 300 µL of 1X wash buffer followed by
the addition of 100 µL of TMB substrate per well, mixed gently for 10 secs, cover and incubated
the plate on a plate shaker (approximately at 200 rpm) at room temperature until the samples
turned dark blue. The reaction was stopped by adding 50 µL of stopping solution to all wells and
mixed gently. The absorbance was measured at 450 nm with SpectraMAX 190 (Molecular
Devices). GMC1 at each dosing concentration was assayed independently at least 3 times (3
replicate assays) with duplicate wells per each replicate assay.
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3.2.5 Cell Proliferation Assay
LNCaP, 22Rv1, and PC3 cells were used to evaluate GMC1 effects on androgendependent AR-mediated proliferation using CellTiter96® Non-Radioactive Cell Proliferation
Assay (Promega). The experiments were performed according to manufacturer’s instructions.
The cells were plated at a density of 5 x 103 cells per well in 96-well plates in 100 µL of
respective standard growth media as detailed above modified by replacement of 5% FBS with
5% CS-FBS incubated 24 h at 37°C in a humidified 5% CO2 atmosphere. The cells were treated
with DMSO + EtOH (negative control), DMSO + synthetic agonist (R1881, 1 nM, positive
control), or the synthetic agonist with a range of GMC1 concentrations (1 µM, 25 µM, 50 µM,
75 µM, and 100 µM) for 18-20 h with the exception of PC3; they are androgen-independent
prostate cancer cells, therefore, there was no need for the addition of the hormone for the assay.
Next day, 15 µL of the Dye Solution were added to each well of GMC1/hormone treated cells
and incubated at 37°C in a humidified environment with 5% CO2 for 4 h. After incubation, 100
µL of the Solubilization/Stop Mix were added to each well and mixed gently to get a uniformly
colored solution. The absorbance were then recorded at 570 nm using a 96-well plate reader
with the use of a reference wavelength at 660 nm to reduce background contributed by cell
debris, fingerprints, and other nonspecific absorbance. GMC1 at each dosing concentration was
assayed independently twice (2 replicate assays) with quadruple wells per each replicate assay.
3.2.6 Statistical Analysis
All results for the experiments are presented as means ± standard deviation and displayed
as the average of at least duplicate biological samples in a single experiment. Each experiment
was repeated at least two independent times. The graphs were presented as an average in a
single experiment except for Western immunoblot analysis: representative blots from each
experiment were shown. One-way ANOVA followed by a post-test of Bonferroni’s Multiple
Comparison statistical analysis was performed to analyze the results using GraphPad PRISM. In
LNCaP AR-dependent PSA luciferase activity experiments, the mean normalized values from
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each dosage concentration for each inhibitor were compared with respective positive control to
compare inhibitory effects on promoter activity by using Student’s paired t test. Differences
were considered to be statistically significant at p ≤ 0.05. Throughout the manuscript, the
following convention was used to denote levels of statistical significance: ***, p ≤ 0.001; **, p ≤
0.01; * p ≤ 0.05.
3.3 RESULTS
3.3.1 GMC1 Demonstrates FKBP52-Specific Inhibition of GR and PR-Mediated Functions
As aforementioned in Chapter 1, FKBP52 functionally potentiates AR, GR, and PR
activities, but not ER nor MR despite the significant sequence, structural, and/or functional
homology that exists between some SHRs. It has been proven that the co-chaperone’s prolinerich loop overhanging the PPIase catalytic pocket in the FK1 domain is responsible for the
regulation of receptor activity. Thus, our resulting lead molecule GMC1 that is predicted to bind
the FKBP52 pocket resulting in re-orientation of the loop disrupting its interaction with receptors
should theoretically also display FKBP52-specific inhibition of both GR and PR as observed
with AR (Fig.2.2b), but not ER activity.
GMC1 demonstrated increased potency with maximal inhibition of GR-mediated reporter
gene expression in MDA-kb2 cells, which express both AR and GR-responsive luciferase
reporter genes, at 100 µM and an IC50 value of 2.69 µM (Fig. 3.1a). GMC1 specifically
inhibited FKBP52-regulated GR and PR activities in 52KO MEF cells, a true FKBP52 negative
background cellular model for testing the co-chaperone-specific effects of the lead molecule, at
low micromolar concentrations with IC50 values of 1.098 µM and 4.080 µM, respectively (Fig.
3.1b-c).
T47D-KBluc is a breast cancer cell line that endogenously expresses ERα and ERβ that
has been stably transfected with a triplet estrogen-responsive-element (ERE)-promoter luciferase
reporter gene construct [229]. This cell line does not require transfection and thus provides a
sensitive and yet, an inexpensive tool for testing GMC1 effects on ER activity. If GMC1 is an
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inhibitor that truly acts via direct targeting of FKBP52, then it should not exhibit inhibitory
effects on ER. As evident in Figure 3.1d, the lead molecule displayed no statistically significant
inhibition of ER-mediated expression of the luciferase reporter after the cells were treated with a
range of concentrations of GMC1 for 16-20 h.
In summary, data here along with the results evident in Figure 2.2a and 2.2b demonstrate
that GMC1 is a promising lead molecule that displays inhibition of FKBP52-mediated functional
effects on SHRs. GMC1 inhibits AR and GR-mediated signaling in MDA-kb2 cells similarly,
but did not functionally affect ER-regulated activity in T47D-KBluc.

Importantly, GMC1

demonstrated inhibitory effects on FKBP52-specific AR, GR, and PR functions in 52KO MEF
cells with IC50 values in high nanomolar to low micromolar concentrations.
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Figure 3.1: GMC1 Inhibits FKBP52-Specific GR and PR-Mediated Activity
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Fig. 3.1: GMC1 Inhibits FKBP52-Specific GR and PR-Mediated Activity. (a) MDA-kb2
cells expressing stably transfected AR and GR-responsive luciferase reporter genes were treated
with 50 nM DEX and a range of GMC1 concentrations (0, 0.01, 0.1, 1, 10, and 100 µM) for 1620 h for testing GR-dependent activity. The graph depicts an average of three independent
receptor-mediated luciferase reporter experiments. (b-c) The graphs show an average of three
independent luciferase reporter assays in 52KO MEF cells in the presence and absence of
FKBP52 treated with 50 nM DOC and 500 nM DOC, respectively, and a range of
GMC1concentrations (0, 0.001, 0.01, 0.05, 0.1, 0.5, 1, 10, 100 µM) for the assessment of
FKBP52-specific GR-mediated activity.

The same experimental conditions and GMC1

concentrations were used for the examination of FKBP52-specific PR-mediated signaling with
the exception of the ligand and its concentrations. P4 serves as an agonist for PR of which 100
pM and 2.5 nM were used to treat the cells in the presence or absence of the co-chaperone,
respectively. (d) T47D-KBluc cells express ERα and ERβ, hence were used to determine GMC1
effect on ER-regulated activity. They were treated with 10 pM E2 and a range of GMC1
concentrations (0, 0.001, 0.01, 0.05, 0.1, 0.5, 1, 10, 100 µM) for 16-20 h. Each IC50 value in the
figure is represented as means ± s.d. of an average of three independent experiments.
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3.3.2

GMC1 Impairs PSA Expression in Prostate Cancer Cellular Models
We examined the effect of GMC1 on the ligand-dependent PSA secretion by assaying the

supernatant of 22Rv1 and LNCaP prostate cancer cells by ELISA. The values were normalized
and statistical analyses were performed against no drug treatment. As shown in Figure 3.2a-b,
GMC1 effectively inhibited PSA secretion in both cell lines in a dose-dependent manner. 22Rv1
expresses both a full length AR and a constitutively active truncated form of the receptor lacking
the C-terminal LBD.

As a result, it can both respond to hormone and display hormone-

independent growth. Figure 3.2c-d show the relative basal and hormone-induced activities of
PSA expression in the presence and absence of ligand, GMC1, and MJC13 [166]. As expected,
under androgen-free condition, there was a low level of basal PSA secretion in 22Rv1 and the
addition of DHT induced the protein expression at least 2 fold. Interestingly, the treatment of
these cells with GMC1 in the absence of hormone reduced basal constitutively active ARdependent PSA secretion by approximately 50% (Fig. 3.2c) as compare to MJC13 [166], which
is an androgen receptor surface-directed antagonist and exhibits no inhibitory effects on PSA
expression (Fig. 3.2d). This data demonstrates that the observed dose-dependent inhibition of
PSA secretion in the experiment was a true phenomenon and was a drug-dependent effect. The
data also suggest that GMC1 has effects on basal activity mediated by the truncated AR protein
in 22Rv1 cells.
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Figure 3.2: GMC1 Reduces AR-Dependent PSA Secretion in Prostate Cancer Cells

67

Figure 3.2: GMC1 Reduces AR-Dependent PSA Secretion in Prostate Cancer Cells. Results
are presented as means ± s.d. with the average of three independent ELISA assays measuring
androgen-dependent PSA secretions from 22Rv1 (a) and LNCaP (b) prostate cancer cells. The
cells were treated with DHT (1 nM and 50 nM for 22Rv1 and LNCaP, respectively) and a range
of indicated concentrations of GMC1 (0, 1, 25, 50, 75, and 100 µM). Data are expressed as a
percentage with the level of PSA in the absence of the compound for each condition set to 100%.
The effects of GMC1 and MJC13 on the basal and hormone-induced activities of PSA
expressions were assessed by ELISA (c) and qPCR (d). (c) Cells were treated with presence and
absence of hormone (1 nM) and GMC1 (100 µM) for 24 h. (d) The data was previously
performed and described by our lab [166]. Experiments were performed in duplicate with data
shown as relative PSA level in media (c) and as PSA expression relative to 18S rRNA (d). The
asterisks denote a statistically significant difference as compared to no GMC1 treatment with
only the presence of DHT. *P ≤ 0.05, **P ≤ 0.01, and *** P ≤ 0.001 were calculated by OneWay ANOVA followed by Bonferroni’s multiple comparison test compared with control.
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3.3.3 GMC1 Reduces Transactivation of PSA Promoter in LNCaP Cells
An

androgen-responsive

luciferase

reporter

plasmid

containing

the

PSA

promoter/enhancer in transiently transfected LNCaP cells was used to examine the effect of
GMC1 on the androgen-dependent transcription of endogenous PSA in LNCaP PCa cells. As
shown in Fig. 3.3a, the inhibitor reduced the DHT-dependent PSA promoter activity in a
concentration-dependent manner. Specifically, GMC1 treatment in the presence of hormone
displayed a significant decrease in activity starting at 30 µM, which is comparable with effective
concentrations in both the PSA ELISA (Fig. 3.2) and luciferase reporter assays (Fig. 2.2). For
comparison, the effects of known and well-characterized AR antagonists, MJC13, MDV3100,
and Bicalutamide, were also assessed. Interestingly, our initial lead molecule, GMC1, which has
not been optimized structurally to improve its efficacy, reduced transactivation of the PSA
promoter activity at a concentration range comparable to MJC13 and classic antiandrogens tested
in this study of which the chemical structure has been optimized with well-characterized
pharmacological, toxicity profiles, and/or has been used as standard ADT treatments.
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Figure 3.3: GMC1 Suppresses Androgen-Dependent PSA Promoter Activation at
Concentrations Comparable to MJC13 and Classic AR Antagonists in LNCaP
LNCaP cells were transiently transfected with androgen-responsive luciferase reporter plasmids
containing PSA promoter. They were treated with the indicated concentrations of GMC1 (a),
MJC13 (b), MDV3100 (c), and Bicalutimide (d) for 24 h. FBS served as the source of the
hormone.

Each promoter-dependent transcription is shown as relative promoter-dependent

luciferase activity. The asterisks denote a statistically significant difference as compared to no
drug treatment with only the presence of hormone. *P ≤ 0.05 and **P ≤ 0.01 were calculated by
Student’s t-test compared with no treatment control.
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3.3.4 GMC1 Decreases Endogenous AR Protein Expression in Prostate Cancer Cells
We examined the effect of GMC1 on the regulation of the AR protein level in both
LNCaP and 22Rv1 cells.

In 22Rv1 cells the full length AR has a molecular mass of

approximately 110 kDa (Fig. 3.4a).

Additionally, a prominent smaller AR-specific protein

species was detected at approximately 80 kDa, which represents the truncated AR that lacks the
C-terminal LBD (Fig 3.4a). In the presence of DHT without GMC1 treatment, the hormone
increased the endogenous full length AR level in both cell lines by enhancing the protein’s
stability (data not shown). However, immunoblot and densitometry analyses of the expressed
AR protein after 24 h of treatment with a range of GMC1 concentrations revealed that the
molecule significantly suppressed androgen-stimulated receptor protein expression in both PCa
cells in a dose-dependent manner (Fig. 3.4). As a control for normalization, GMC1 did not
affect GAPDH expression (Fig. 3.4a-b). It is important to note that only the full length AR
levels in 22Rv1 and LNCaP cells were significantly inhibited by GMC1, not the truncated
receptor product in 22Rv1.

Therefore, the molecule only inhibited androgen-dependent

endogenous full length AR protein levels. Interestingly, GMC1 began to significantly suppress
the androgen-dependent induction of AR activity in 22Rv1 at 0.5 µM compare to LNCaP in
which 50 µM of the inhibitor was required to considerably affect the receptor level (lower panels
of Fig. 3.4a-b).
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Figure 3.4: GMC1 Decreases Endogenous Androgen-Dependent AR Expression in Prostate
Cancer Cellular Models
The effects of GMC1 on hormone-dependent endogenous AR expression were assessed in
22Rv1 (a) and LNCaP (b) cells by Western immunoblot and densitometry. Lysates from cells
grown in the presence and absence of the indicated concentrations of hormone and GMC1 for 24
h were electrophoresed and immunoblotted for AR and GAPDH (loading control) and the
protein levels were quantified via densitometry. The upper panels show the representative
Western immunoblots.

The lower panels represent averaged densitometry data from three

independent experiments. Data are displayed as AR level relative to that of loading control,
which then calculated as a percentage with the endogenous expression of the receptor in the
absence of the compound for the condition set to 100%. The asterisks denote a statistically
significant difference as compared to no GMC1 treatment with only the presence of DHT. *P ≤
0.05, **P ≤ 0.01, and *** P ≤ 0.001 were calculated by One-Way ANOVA followed by
Bonferroni’s multiple comparison test compared with control.
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3.3.5 GMC1 Reduces Endogenous AR-Dependent Gene Expression in Prostate Cancer
Cells
PSA is a clinically important biomarker for PCa and it is also a well-known AR-regulated
gene in the human prostate gland of which the expression is mainly induced by androgen and
regulated by the receptor at the transcriptional level [230]. Besides the canonical AR target PSA,
the 51-kDa FK506-Binding Protein (FKBP51), a SHR-associated co-chaperone, is another
androgen-regulated gene and has been shown to physically interacted with the AR, promoting
receptor signaling, and leading to increased FKBP51 expression in PCa [196, 231].

The

hyperexpression of FKBP51 leads to a stimulation of chaperone complex association with AR,
which further increases the receptor transcriptional activity by establishing an ultra-short positive
feedback loop [196]. This feed-forward mechanism amplifies AR signaling even under a low
hormone condition, which often occurs during androgen ablation, allowing FKBP51 to continue
to increase the transcriptional activity of the receptor in the absence of hormone [149, 231, 232].
Furthermore, the knockdown of FKPB51 dramatically decreases its hormone-dependent gene
transcription and protein expression in PCa cells [149, 232]. Thus, FKBP51 has emerged as a
potential novel diagnostic biomarker and/or target for PCa therapy [233, 234]. Taken together, it
is important to demonstrate GMC1 can reduce the endogenous level of PSA and FKBP51 in
prostate cancer cellular models. We assessed the impact of our lead molecule on the ARregulated genes by Western immunoblot and densitometry in 22Rv1 and LNCaP cells (Fig. 3.5).
Representative blots for FKBP51, PSA, and the loading control GAPDH are shown (Fig. 3.5a-b,
upper panels). In the presence of DHT without GMC1 treatment, the hormone increased the
endogenous hormone-dependent PSA and FKBP51 levels in 22Rv1 and LNCaP cells as
observed in the literature (data not shown). The normalized average densitometry data from
three independent experiments demonstrate that GMC1 reduced endogenous androgendependent AR-mediated FKBP51 and PSA gene expression in a dose-dependent manner in both
prostate cancer cellular models (Fig. 3.5a-b, lower panels). Interestingly, the lead molecule was
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observed to suppress the DHT-dependent induction of FKBP51 transcript level more effectively
in 22Rv1 as compare to LNCaP, and the reverse was observed for PSA gene expression.
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Figure 3.5: GMC1 Reduces Endogenous AR-Dependent Gene Expression in Prostate
Cellular Models
The effects of GMC1 on AR-dependent endogenous gene expression were assessed in 22Rv1 (a)
and LNCaP (b) cells by Western immunoblots and quantified via densitometry. Lysates from
cells grown in the presence and absence of the indicated concentrations of hormone and GMC1
for 24 h were electrophoresed and immunoblotted for FKBP51, PSA, and GAPDH (loading
control) and the protein levels were quantified via densitometry. The upper panels show the
representative Western immunoblots. The lower panels represent averaged densitometry data
from three independent experiments. Data are displayed as FKBP51 and PSA levels relative to
that of loading control, which then calculated as a percentage with the endogenous expression of
the proteins in the absence of GMC1 of which the condition is set to 100%. The asterisks denote
a statistically significant difference as compared to no GMC1 treatment with only the presence of
DHT.*P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001 were calculated by One-Way
ANOVA followed by Bonferroni’s multiple comparison test compared with control.
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3.3.6 GMC1 Inhibits AR-Dependent Proliferation in Prostate Cancer Cellular Models
Abnormal cell proliferation rate is one of the characteristics of cancer, which led us to
examine the effects of GMC1 on androgen-dependent PCa cell growth using CellTiter96® NonRadioactive Cell Proliferation Assay in 22Rv1 and LNCaP cells. All treatments were carried out
in a steroid-depleted condition containing charcoal-stripped serum. In basal conditions, synthetic
androgen R1881 treatment enhanced AR-regulated 22Rv1 and LNCaP proliferation during a 24hour treatment and the combination of hormone with GMC1 decreased cell growth in a
concentration-dependent manner (Fig. 3.6a-b). For comparison, PC3, an AR-negative cell line,
was used to demonstrate that the observed inhibitory effects on 22Rv1 and LNCaP were indeed
receptor-dependent phenomenon. GMC1 has no effects on the proliferative rate of PC3 cells
(Fig. 3.6c), which demonstrates that the molecule down-regulated AR-dependent cell growth. It
is noted that the molecule appears to reduce LNCaP proliferation without the presence of
hormone at 75 µM and 100 µM. The observed phenomenon might be related to cytotoxicity
effect of GMC1 on the cells at those concentrations (Fig. 3.6b). Nevertheless, the trend of
GMC1 inhibiting cell growth in an androgen-dependent AR-mediated manner is undeniable.
Furthermore, statistical analyses of each data point comparing the cell growth in the absence to
the presence of R1881 demonstrated that proliferation was significantly reduced under hormonedependent conditions at each respective GMC1 concentration.
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Figure 3.6: GMC1 Down-Regulated Hormone-Dependent AR-Specific Proliferation in
Prostate Cancer Cellular Models
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Fig. 3.6: GMC1 Down-Regulated Hormone-Dependent AR-Specific Proliferation in
Prostate Cancer Cellular Models.

GMC1 effectively inhibited androgen-dependent AR-

mediated prostate cancer cell growth. Cells were treated in the presence or absence of 1 nM
synthetic androgen, R1881, and GMC1 at 0, 1, 25, 50, 75, and 100 µM for 24 h. The absorbance
was measured at 570 nM using the appropriate reference wavelength at 660 nM. The graphs are
representative of three independent experiments with similar results for 22Rv1 (a), LNCaP (b),
and PC3 (c). The AR-negative PC3 cells were used as a control for AR-specificity for the
prostate cancer cell growth. GMC1 did not have any effect on the proliferation of the PC3 cells
(c). Data at each GMC1 concentration are normalized to the absence of drug treatment in the
respective experimental conditions (+/- R1881). The normalized results are calculated as a
percentage in the absence of the compound, which is set to 100%. The asterisks denote a
statistically significant difference between the presence and absence hormone at each GMC1
concentration. Significant differences at each GMC1 concentrations are indicated (**** P ≤
0.0001), which were calculated by One-Way ANOVA followed by Bonferroni’s multiple
comparison test.
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3.4 DISCUSSION
As discussed in Chapter 1, prostate cancer patients, over time, often develop resistance to
ADT and invariably progresses switching the antiandrogens from antanonists to agonists of the
AR via alternative pathways, such as GR.

GR becomes a substitution for the AR to activate

similar but distinguishable sets of target genes, which is necessary for maintenance of the
resistant phenotype [159]. In addition, studies have shown there is a correlation with PR and
prostate tumor progression. PR expression is often elevated during the progression of metastatic
and androgen-insensitive prostatic adenocarcinoma [200, 201]. Given FKBP52 is a specific
positive regulator of AR, GR and PR signaling, and GMC1 is predicted to be an FKBP52
PPIase-targeting drug, the molecule should inhibit co-chaperone-specific GR and PR functions
as demonstrated in AR (Fig. 2.2). In this study, we have shown that our novel lead molecule,
GMC1, specifically inhibited FKBP52-enhanced GR and PR activity in a mammalian cell line,
which provided a true FKBP52-negative background to test for the co-chaperone-specific effects
of the candidate drug. The IC50 values for both receptor inhibitory curves were determined at
low micromolar concentrations by functional screens consisting of two receptor-mediated
luciferase assays assessing drug effects on general receptor activity and FKBP52 specificity (Fig.
3.1a-c). Furthermore, GMC1 did not affect ER function, which is not regulated by FKBP52 thus
confirming the molecule’s FKBP52-specific effects (Fig. 3.1d).
PSA is a serine protease that is synthesized by both normal and malignant epithelial cells
of the human prostate. Under a malignant condition, PSA is expressed at an elevated level which
is released into serum and has been proven to be highly correlated with prostate tumor recurrence
and progression [230, 235]. We demonstrated that GMC1 effectively reduces PSA secretion.
ELISA analysis of PSA levels from 22Rv1 and LNCaP cells showed that GMC1 reduces
androgen-dependent AR-mediated PSA secretion from both cell lines in a dose-dependent
manner (Fig. 3.2a-b). Interestingly, GMC1 was also able to inhibit constitutive PSA expression
but not the AR surface-directed antagonist MJC13 (Fig. 3.2c-d).
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Next, we evaluated GMC1 on the transcriptional activity of AR using LNCaP cells using
a transiently transfected androgen-responsive luciferase reporter plasmid containing the PSA
promoter/enhancer. GMC1 reduced the receptor transactivation activity at a range of
concentrations comparable to the structurally optimized MJC13 and clinically used
antiandrogens, Bicalutamide and MDV3100, which suppress AR signaling by preventing
hormone-induced receptor-chaperone complex dissociation or by direct interaction with the AR
LBD (Fig. 3.3). These data suggest that our initial hit molecule, which has not been structurally
optimized, could be optimized to a more potent analog that would display significantly increased
potency as compared to MJC13, MDV3100, and Bicalutamide.
We have demonstrated that our lead molecule, GMC1, reduced endogenous levels of
androgen-dependent AR-regulated PSA and FKBP51 gene expression and effectively inhibited
prostate cancer cell proliferation in a concentration-dependent manner (Fig. 3.5 and 3.6). These
results correlated with GMC1-mediated downregulation of androgen-responsive full-length AR
in a dose-dependent manner (Fig. 3.4). As aforementioned in Chapter 1, FKBP52 association
with SHR-chaperone complexes establishes a functionally mature conformation necessary for
enhancement of hormone binding to the receptor and leading to its subcellular localization.
Thus, GMC1 disruption of the interaction between FKBP52-AR heterocomplex may affect the
hormone binding affinity of the receptor. As a result, AR dissociates from the mature chaperone
complex, the free receptor re-enters the chaperoning cycle, and eventually is degraded by
targeting them to the ubiquitin/proteasome pathway (Fig. 3.4). As a consequence, AR-dependent
gene expression and hormone-stimulated proliferation in PCa cells are inhibited (Fig. 3.5 and
3.6).
In summary, in vitro studies performed in this chapter demonstrated that the GMC1 is a
promising hit molecule that displayed similar inhibition of FKBP52-regulated GR and PRmediated activities.

GMC1 reduced the AR transactivation of hormone-responsive PSA

promoter in prostate cancer cells. It also induced AR de-stabilization leading to reduced AR
protein levels in 22Rv1 and LNCaP cells. Furthermore, GMC1 inhibited endogenous androgen80

dependent AR-regulated gene expressions and PSA secretions, and down-regulated cell
proliferation at concentrations consistent with those observed to be effective in reporter assays.
Here, we demonstrated that “indirect AR targeting”, specifically direct targeting of FKBP52, is a
promising strategy in combating PCa.

Our data suggest that small molecules binding to the

PPIase pocket can re-orient the proline-rich loop and affect its interaction with the receptor, thus
further highlighting the importance of the architectural integrity of the loop during FKBP52mediated receptor functions.
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CHAPTER 4: VERIFICATION OF GMC1 TARGET SITE AND
PRELIMINARY ANIMAL EVALUATIONS
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4.1 RATIONALE
In Chapter 2, we used in silico-based docking prediction to screen 3 million lead-like
small molecules from the ZINC database targeting the FKBP52 PPIase pocket, which resulted in
40 hit molecules. From those 40 compounds we identified GMC1 as the initial hit molecule for
further in vitro characterization. However, the identification was based on predictive modeling
that relies on three key hydrogen bond interactions between residues Asp68, Ile87, and Tyr113 in
the catalytic pocket and the selected compounds including GMC1. Thus, it is imperative for us
to verify that GMC1 does in fact bind to the PPIase pocket through hydrogen bonding with those
residues and/or any other residues within the catalytic cavity. In order to confirm that GMC1
directly bind to the intended target site on the PPIase pocket, we designed and constructed amino
acid mutations that may alter the predicted binding site of the compound, disrupting drug
inhibition, while not affecting the FKBP52’s ability to potentiate AR activity.
Hitherto, we have performed detailed molecular and cellular evaluations of GMC1 and
demonstrated its potential as an effective therapeutic treatment of PCa. In this study, we sought
to investigate whether the lead molecule’s effects on an animal xenograft model of CRPC
corroborate with the results from the in vitro studies. Unfortunately, due to a lack of hydrophilic
functional groups and unavailable basic physicochemical information about our lead compound,
the development of a suitable formulation for GMC1 to deliver in vivo has been a challenging
task.

Therefore, our collaborator, Dr. Xie from Texas Southern University has led

preformulation studies of GMC1 to determine its physicochemical properties and developed an
optimal formulation for the lead molecule that was suitable for administration into mouse
prostate cancer model. The formulated GMC1 was then administered and evaluated in a CRPC
xenograft mouse model by our collaborator, Dr. Chaudhary’s group from Clark Atlanta
University.
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4.2 MATERIALS AND METHODS
4.2.1 Cell Culture
52KO MEFs were acquired and maintained as described in Chapter 2.2.3.
4.2.2 Transient Transfection and Luciferase Reporter Assay
52KO MEF luciferase reporter assays were performed as described in Chapter 2.2.4. The
plasmids used here were the same as previously described except for the addition of FKBP52D68A (800 ng per well), FKBP52-V86A (800 ng per well), FKBP52-I87A (800 ng per well),
and FKBP52-Y113A (800 ng per well) to the experiments.

These mutants were directly

generated in the pCI-Neo mammalian expression vector expressing FKBP52 using the Quick
Change II Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s
instructions.

Each functional mutagenesis experiment contains the following plasmids: a

constitutive β-galactosidase expression plasmid (50 ng per well; transfection control), a
hormone-responsive firefly luciferase reporter (400 ng per well), a pCI-Neo mammalian
expression vector (800 ng per well; Promega) expressing AR (800 ng per well), an empty pCINeo mammalian expression vector (800 ng per well; negative control), a pCI-Neo mammalian
expression vector expressing FKBP52 (800 ng per well; positive control), and a pCI-Neo
mammalian expression vector expressing either FKBP52-D68A (800 ng per well), FKBP52V86A (800 ng per well), FKBP52-I87A (800 ng per well), or FKBP52-Y113A (800 ng per well).
4.2.3 GMC1 Formulation
4.2.3.1 Solubility
A liquid chromatography-mass spectrometry and liquid chromatography-tandem mass
spectrometry (LC-MS/MS) method was developed and validated for GMC1, which was custom
synthesized (purify ≥ 99%) by ChemBridge Corporation (San Diego, CA), to determine the
concentration of GMC1 in various solvents. The provisional solubility (n = 1) of GMC1 in
water, soybean oil, oleic acid, Tween 80, capyrol (propylene glycol type 1), EtOH, cremophor,
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labrasol, polyethylene glycol 400 (PEG 400), polyethylene glycol 300 (PEG 300), DMSO, N, Ndimethylacetamide (DMA) was determined by shake-flask method.
4.2.3.2 Lipophilicity
The lipophilicity of GMC1 was examined as the logarithm of partition coefficient (logP)
of the solute between water and 1-octanol using the shaker method. The logP was calculated
according to Equation 1:
LogP = log 𝑪𝑪𝒘𝒐

(1)

where Co and Cw represents the concentrations of GMC1 in 1-octanol and aqueous phase,
respectively.
4.2.3.3 Plasma Protein Binding
In vitro healthy human plasma samples of GMC1 were prepared by diluting the stock
solution with acetonitrile and spiking in the plasma at five different concentrations: 100, 500,
1000, 2000, and 5000 ng/mL to evaluate GMC1 plasma protein binding. The fraction unbound
GMC1 (fu) was determined as Equation 2:
𝑓𝑢 =

𝑐𝑢

(2)

𝑐𝑡

where Cu is the unbound concentration and Ct is the total concentration. The plasma protein was
then determined by 1 – fu.
4.2.3.4 Co-Solvency
Co-solvent systems with various compositions and ratios of labrasol, PEG 300, and DMA
were prepared with GMC1 concentration at 5 mg/mL and 10 mg/mL. Each system was diluted
with normal saline at the ratios of 1:1, 1:4, 1:9, 1:19 (v/v), then the optimal formulation for
GMC1 was selected based on its solubility, precipitation upon dilution, and solvent toxicity. The
optimal co-solvent formulation of GMC1 was stored at 4°C and analyzed via LC-MS/MS to
determine the amount of GMC1 present.
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4.2.4 Xenograft Mouse Model
4.2.4.1 Preparation of Tumor Cells
LNCaP-Inhibitor of differentiation 4 (Id4) cells were grown in a complete medium (10%
volume/volume (v/v) FBS in RPMI 1640 medium).

LNCaP-Id4-/- cells were generated as

previously described [236, 237]. Id4 was stably silenced in LNCaP cells using a gene specific
small hairpin RNA (shRNA) retroviral vector (Open Biosystems #RHS1764-97196818).
Successful Id4 gene silencing was confirmed by qRT-PCR and Western immunoblot analyses.
When cells were 70-80% confluent, 3-4 h before harvesting, medium was replaced with fresh
medium to remove dead and detached cells. Then the fresh medium was removed, and cells
were washed with PBS. After adding a minimum amount of trypsin-EDTA, cells were dispersed
by adding complete medium (5:1), and then centrifuged immediately at 1500 rpm for 5 min.
After re-suspending the cell pellet with complete medium (1:1), cells were counted using a
hemocytometer.
4.2.4.2 Tumor inoculation
The work area was prepared by disinfecting all hood surfaces with 70% ethanol. The
inoculation area of each mouse was cleaned and sterilized with an alcohol pad. A freshly
prepared cell suspension was agitated to prevent the cells from settling, and then mixed with
matrigel. One µL of the mixture (containing 2 × 106 cells) was injected subcutaneously into the
lower flank of each of the 14 (4-week old) castrated NCRNU-Male Athymic Nude mice
(Taconic Biosciences) using a 27-gauge syringe. Tumor diameters were measured with digital
calipers, and the tumor volume was calculated each week using the Equation 3:
𝑉=

𝑊2 x 𝐿
2

(3)

where V is the tumor volume, W is the tumor width, and L is the tumor length. At the end of the
experiments, the mice were laid to rest by asphyxiation, the tumors were surgically removed,
weighed, and the volume was measured.
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4.2.5 Preclinical Efficacy
GMC1 drug therapy was started 4 weeks after inoculation, when the tumors reached an
average volume of about 100 mm3. Mice were randomized into two groups with 7 mice in each
group. The work area was prepared by disinfecting all hood surfaces with 70% ethanol. The
tumor site of each mouse was cleaned and sterilized with an alcohol pad. The test group was
administered 5mg/kg GMC1 by intratumoral administration in the optimal co-solvent
formulation twice weekly for four consecutive weeks. The control group was administered the
equivalent amount of co-solvent vehicle without GMC1 following the same schedule. Tumor
volumes were recorded prior to each treatment.
4.2.6 Statistical Analysis
Data analyses were performed and figures were generated as described in Chapter 3.2.6.
Experiments in section 4.2.3 were conducted in triplicate. Tumor volumes were analyzed using
One-Way ANOVA followed by Bonferroni’s multiple comparison test to determine the
significance between test and control groups at each time point. Statistical significance was
reported if P value was ≤ 0.05.
4.3 RESULTS
4.3.1 Characterization of GMC1 Binding to PPIase Catalytic Pocket with Competitive
Fluorescence Polarization Assay
Fluorescence polarization (FP) is a powerful tool that is often used to study molecular
interactions including SHR-ligand binding by measuring the polarization value of a weighted
average of the bound versus unbound states of the fluorescent molecules [238, 239]. Our
collaborator, Dr. Felix Hausch and his laboratory from Max Planck Institute for Psychiatry,
developed and performed FP assays for the competition of fluorescently-labelled tracers with
FK506 (Tacrolimus), which is a known FKBP52 binder, and GMC1 for binding to the FKBP52
PPIase pocket to verify the GMC1 target site. Given the observed effects on the FKBP52specific receptor-mediated luciferase functions and in vitro studies in prostate cancer cellular
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models, we were surprised that the competitive binding of GMC1 to FKBP52 was not detected in
FP experiments (data not shown). However, GMC1 is a much smaller molecule that is predicted
to have only half of the binding affinity to the catalytic pocket compared to FK506 (data not
shown). As a result, it is likely that GMC1 simply failed to displace FK506 from the PPIase
pocket.

Therefore, we have generated functional FKBP52 PPIase mutants, which should

maintain potentiation of the receptor activity but influence GMC1 inhibition if the drug does
target the predicted binding sites from the docking simulations.
4.3.2 Identification of GMC1 Target Site on PPIase Catalytic Pocket Using Functional
Mutagenesis Studies
We have identified D68, I87 and Y113 as three key residues within the FKBP52 PPIase
pocket that form important hydrogen bond interactions with ligands in Chapter 2. GMC1 was
predicted to bind through these specific residues within the catalytic pocket and induce reorientation of the proline-rich loop disrupting the co-chaperone’s interaction with SHRs.
Interestingly, based on the molecular docking model depicted in Figure 6, we have observed that
Val86 within the PPIase pocket is also predicted to form a close interaction with GMC1 although
it does not create a hydrogen bond with the molecule. Thus, we generated FKBP52-D68A,
V86A, I87A, and Y113A mutants via site-directed mutagenesis and performed functional
luciferase studies to assess the effects that the mutations have on GMC1's ability to inhibit
receptor activity.
The FKBP52-D68A, V86A, I87A, and Y113A mutants were first evaluated to confirm
these mutations within the PPIase pocket did not impair FKBP52-mediated potentiation of the
AR activity in 52KO MEFs. Any mutants that did not obstruct the potentiation ability of
FKBP52 were subsequently tested for the co-chaperone-enhanced receptor-mediated luciferase
expression in the presence of GMC1. As shown in Figure 4.1, mutations at positions D68, V86,
and I87 did not impair FKBP52 potentiation of the receptor function, but the Y113A mutant did.
Therefore, only the FKBP52-D68A, V86A, and I87A mutants were further assessed for their
effects on GMC1 inhibition. In comparison to FKBP52-WT, the mutation at position D68 in
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PPIase pocket caused GMC1 to have a two-fold decrease in the inhibition of FKBP52-regulated
AR activity (Fig. 4.2).
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Fig. 4.1: FKBP52 PPIase Domain Mutants and Receptor Function
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Fig. 4.1: FKBP52 PPIase Domain Mutants and Receptor Function. (a-c) Site-directed
mutagenesis mutants at residues D68, V86, and I87 within the FKBP52 PPIase pocket maintain
the FKBP52 potentiation of AR function.

However, this co-chaperone-enhanced receptor

activity is significantly decreased for FKBP52-Y113A mutant (d). AR, the receptor-inducible
reporter plasmid, and the constitutively active β-galactosidase reporter plasmids were cotransfected simultaneously with each of the plasmids indicated for the different treatment groups
in 52KO MEFs. Cells were induced at 10 pM DHT or EtOH for 16-18 h. Following cell lysis,
AR expression was assessed by luciferase assay. The data represents the averaged reporter
expression (luciferase activity/β-galactosidase activity ± s.d.) of at least two replicates. The
asterisks denote a statistically significant difference by comparing the FKBP52-mutants to WT
with only the presence of DHT. **P ≤ 0.01 was calculated by One-Way ANOVA followed by
Bonferroni’s multiple comparison tests.
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Figure 4.2: FKBP52-D68A PPIase Domain Mutants Disrupted GMC1 Binding and
Affected Its Inhibitory Effect on Receptor Function
D68 is the GMC1 binding sites within the FKBP52 PPIase Pocket within the FK1 domain.
FKBP52-D68A mutant affects GMC1 inhibitory effect on the AR-mediated activity by two-fold.
The graph represents an average of three independent luciferase reporter assays in 52KO MEF
cells in the presence of empty pCI-Neo mammalian expression vector (negative control),
FKBP52-WT (positive control), and FKBP52-mutants treated with 1 nM DHT (negative control)
and 10 pM (positive control and mutants), and a range of GMC1concentrations (0, 0.001, 0.01,
0.05, 0.1, 0.5, 1, 10, 100 µM) for the assessment of FKBP52-specific AR-mediated activity.
Each IC50 value is represented as means ± s.d. of an average of three independent experiments.
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4.3.3 Optimal Formulation of GMC1
As aforementioned, GMC1 was predicted to have low aqueous solubility due to its lack
of hydrophilic functional groups, thus, it is important to perform preformulation studies to
establish the lead molecule’s basic physicochemical properties in order to develop a solution
formulation suitable for in vivo administration.
The provisional solubility of GMC1 in water, soybean oil, oleic acid, Tween 80, capyrol,
EtOH cremophor, labrasol, PEG 400, PEG 300, DMSO, and DMA was determined. The results
were summarized in Table 4.1. As evident in the table, GMC1 was not hydrophilic and poorly
soluble in water, but moderate to highly miscible with labrasol, PEG 400, PEG300, DMSO and
DMA. Thus, these water-miscible solvents could be used as solubility enhancers to increase
GMC1 aqueous solubility during formulation studies to improve the dissolution rate and
bioavailability of the drug.
Lipophilicity is another common physicochemical parameter for drug discovery
compounds.

It is needed for the molecules to permeate through the various biological

membranes. The lipophilicity (logP) of GMC1 between water and 1-octanol tested by the shakeflask method was 1.39 ± 0.05, which was within the Lipsinski rule-of-five value (logP < 5)
[240].
The plasma protein binding of GMC1 in healthy human plasma at concentrations of 100,
500, 1000, 2000, and 5000 ng/mL were found to be 71.9 ± 5.4 %, 89.4 ± 1.9 %, 96.0 ± 1.1 %,
97.3 ± 0.7 %, 98.6 ± 0.2 %, respectively. These data indicate that GMC1 is highly plasma
protein bound and the binding is concentration-independent.
Cyclodextrins

(CD)

are

nonreducing,

crystalline,

water

soluble,

and

cyclic

oligosaccharides consisting of glucose monomers arranged in a donut shaped ring having
hydrophobic cavity and hydrophilic outer surface [241]. Given the architectural characteristics
and amphiphilic properties of the cyclodextrin molecules, they are often used to create
complexes with hydrophobic compounds and improving the aqueous solubility, dissolution rate,
and bioavailability of poor water soluble drugs [241, 242]. Our collaborator, Dr. Xie’s group has
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developed an intravenous formulation of GMC1 using 2-hydroxypropyl-β-cyclodextrin (HP-βCD). The solubility of GMC1 in 50% weight/volume (w/v) HP-β-CD solution is 0.75 ± 0.07
mg/mL, which was a 250-fold increase in aqueous solubility. However, a co-solvent system
using the water-miscible solvents from Table 4.1 in various compositions and ratios has proven
to be a better strategic formulation for GMC1 than using cyclodextrin. The optimal co-solvent
formulation for GMC1 is LP4 (Table 4.2), which increased the aqueous solubility of the
molecule by 3333-fold at 10 mg/mL concentration. This formulation system was selected based
on the solubility and precipitation of GMC1 and solvent toxicity, which allowed the drug to be
safely administered to animal subjects orally, subcutaneously, and intravenously. Given the cosolvent formulation improved the GMC1 aqueous solubility by 13-fold in comparison to the CD
formulation and was stable for, at least, 1 month at 4°C. The co-solvent system based on LP4
composition and ratio was the selected optimal solution formulation for GMC1 for in vivo
administration.
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Table 4.1 Solubility of GMC1 in Various Solvents

95

Table 4.2 GMC1 Co-Solvent Systems
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4.3.4 Preclinial GMC1 Efficacy
Our collaborator, Dr. Chaudhary’s group investigated the therapeutic effects of GMC1 on
the regression of tumor size, volume, and weight in the four week-old castrated male athymic
nude mice. The CRPC xenograft mouse models were generated by injecting LNCaP-Id4-/- cells
subcutaneously into the lower flank of mice resulting in aggressive forms of prostate tumors. 5
mg/kg GMC1 treatment began at 4 weeks post-inoculation with tumor volume at approximately
100 mm3 via intratumoral injection twice weekly for a month. As evident in Figure 4.3, GMC1
significantly reduced tumor size, volume, and weight in test (GMC1-treated) group compare to
control (vehicle-treated). The drug treatment began to display inhibitory effects on the tumor
growth at 2-week GMC1-post-injection and reached a significant inhibition of tumor growth at
week 3 and 4 while the tumor volume in the control group continually increased (Fig. 4.3a).
Furthermore, statistical analyses of tumor volumes within the test group revealed a progressive
increase in tumor regression by demonstrating a significant decrease in tumor volume comparing
week 4 post-GMC1-administration with week1 and 2 (**P ≤ 0.01, asterisks not shown in Fig.
4.3a).
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Figure 4.3: Treatment of LNCaP-Id4-/- Generated Prostate Tumor with GMC1
Significantly Decreased Tumor Size and Induced Tumor Regression
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Fig. 4.3: Treatment of LNCaP-Id4-/- Generated Prostate Tumor with GMC1 Significantly
Decreased Tumor Size, Volume, Weight, and Induced Tumor Regression. GMC1 treatment
started 2 weeks post-inoculation of tumor cells by administering 5 mg/kg of the drug twice
weekly for 4 consecutive weeks via intratumoral injection. (a) Tumor diameters were measured
with a digital vernier caliper, then the volumes were calculated using Equation 3 described in
section 4.2.4.2. Data displays the weekly measurements of 4 control tumors vs. 4 GMC1-treated
tumors. The asterisks denote a statistically significant difference between the control and GMC1
treatment groups at each time point. Significant differences are indicated (**** P ≤ 0.0001),
which were calculated by One-Way ANOVA followed by Bonferroni’s multiple comparison test.
(b-d) At the end of the experiment, mice were sacrificed and tumors were extracted along with
the respective measurements of the tumor volume and weight. The data represents an average of
4 tumor measurements per experimental group.

Representative tumor images for each

experimental condition are displayed in (b). The asterisks denote a statistically significant
difference as compared to no drug treatment. **P ≤ 0.01 and ****P ≤ 0.0001 were calculated by
Student’s t-test compared with no treatment control.
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4.4 DISCUSSION
We have generated mutations at D68, V86, I87, and Y113 positions in the FKBP52
PPIase pocket based on the evidence that it forms important hydrogen bonds with GMC1 and/or
establishes pertinent interactions between the residues and our lead molecule. Our collaborator,
Dr. Cherkasov’s group have performed molecular dynamic simulation and alanine-scanning on
the predicted FKBP52-GMC1 complex in which Y113 showed the most reasonable energy
difference between FKBP52-WT and the mutants (data not shown). Interestingly, functional
mutagenesis studies demonstrated that the FKBP52-Y113A mutant abrogated the co-chaperone’s
receptor potentiation function (Fig. 4.1d). This phenomenon could be due to the fact that by
changing tyrosine to alanine at position 113 induced too much structure instability within the
PPIase domain resulting in an abolishment of the co-chaperone’s function. We have observed
that mutation at D68 affected the inhibitory effects of GMC1 on FKBP52-regulated ARmediated activity (Fig. 4.2). The mutant did not impair the molecule’s inhibition of receptor
function completely, but it did demonstrate a reduction trend of the IC50 value by two-fold,
which suggests that GMC1 interacts weakly with D68.
Assessing the physicochemimal properties of drug compounds are typical early steps in
drug discovery. A good compound has high enough water solubility to be able to dissolve to
blood/plasma and other aqueous bodily fluids, whilst also having certain amount of lipophilicity
to permeate across biological membranes (i.e. intestine wall). In this study, our collaborator, Dr.
Xie’s group found that GMC1 was highly plasma protein bound, and the binding is
concentration-independent. Based on the free drug hypothesis, only the free unbound fraction of
a drug at the therapeutic target site exerts pharmacological activity [243]. Thus, it was necessary
and important to develop an appropriate formulation for GMC1 to be delivered to the therapeutic
target biophase for preclinical efficacy studies. The optimal formulation was identified to be
LP4 (Table 4.2), which was selected based on consideration of three factors: GMC1 solubility,
GMC1 precipitation upon aqueous dilution, and solvent toxicity. The LP4 formulation increased
GMC1 aqueous solubility by a 3333 fold at 10 mg/mL, which can be safely administered to
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animal subjects orally, subcutaneously, and intravenously. This optimal formulation was also
found to be stable at 4°C for a minimum of one month.
Given there was no established pharmacokinetic profile on therapeutic window and
toxicity of GMC1, our collaborator, Dr. Chaudhary’s group decided to deliver the drug via
intratumoral injection, thus bypassing the major obstacles associated with systemic delivery
while taking advantage of solid tumor barriers to prevent rapid drug clearance and promote local
drug retention, and lower concentration in healthy tissues [244-246]. The data showed that 5
mg/kg GMC1 twice weekly intratumoral administration with LP4 co-solvent formulation
significantly inhibited the tumor growth and induced tumor regression (Fig. 4.3). Given the
aggressive nature and androgen independence of the LNCaP-Id4-/- tumor model [236, 237], these
findings are encouraging and warrant further preclinical development of GMC1.
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CHAPTER 5: CONCLUSIONS
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PCa is one of the most common cancers and the second leading cause of cancer deaths in
men in industrialized nations and remains a major challenge to treat effectively [247-249]. AR is
an androgen-activated transcription factor that belongs to the nuclear receptor family and plays
an important role in promoting the development of PCa [250]. In addition, studies have shown
that the AR signaling axis remains active as the disease evolves from androgen-sensitive cancer
to castration-resistant [251, 252].

In fact, aberrant AR signaling is a hallmark of CRPC.

Therefore, AR has been the most common therapeutic target for the treatment of PCa and the
mainstay for it is hormone-ablation therapy using antiandrogens and/or ADT [216, 253-256].
Current clinically approved antiandrogens, such as Flutamide (Eulexin) [257],
Bicalutamide (Casodex) [258], and Enzalutamide (MDV3100) [259] prevent androgens from
carrying out their biological function by directly binding and blocking the AR LBD, hence
inducing repressive activity [260, 261]. The efficacy of antiandrogen treatment is temporary,
and typically after a median of 18-24 months, the disease progresses to CRPC, which becomes
nonresponsive to ADT and fatal with no curative therapy available. The antiandrogen resistance
mechanisms are mainly thought to be due to spontaneously acquired mutations in the AR LBD
including T877A, W741L/C, H874Y, and F876L, which convert the drugs from receptor
antagonists to agonists [163, 224, 262-265]. In addition, most of the antiandrogens share the
same structural motif responsible for effective AR LBD binding. As a result, there is an unmet
clinical need in developing treatments for CRPC. Researchers including our lab have focused
their efforts on the development of drugs targeting alternative sites on AR and its regulatory
proteins, and AR inhibitors for which the binding sites are currently unknown [165].
Our lab has developed an AR BF3 surface-directed AR antagonist termed MJC13, which
inhibits FKBP52 regulation of AR by blocking the dissociation of AR-FKBP52-Hsp90 complex
and retaining the hetercomplex in the cytoplasm resulting in a loss of AR nuclear translocation
and inhibition of androgen-dependent gene expression and proliferation in prostate cancer cells
[166]. Additionally, we have shown that MJC13 effectively prevents β-catenin interaction with
the AR LBD and the synergistic up-regulation of the receptor by FKBP52 and β-catenin [192],
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which suggests that the drug might be able to block AR reactivation that occurs in response to
Wnt/β-catenin signaling stimulation in CRPC.
While the targeting of the alternative FKBP52 regulatory surface on AR is a promising
therapeutic strategy as demonstrated by MJC13, a novel drug directly targeting FKBP52 by
interrupting the proline-rich loop interaction with AR would likely be a more potent and
effective strategy in treating PCa. The reasons are illustrated in Figure 1.4. First, the FKBP52
PPIase pocket is an ideal hydrophobic drug binding site and is also a known “druggable” target
as FK506 (Tacrolimus) is already FDA-approved for use in the clinic. Second, given the
conservation of the PPIase pocket across FKBP family members, drugs targeting the FKBP52
PPIase pocket would likely target the closely related FKBP51 protein, which is also a positive
regulator of AR in PCa [196]. Third, FKBP52 is a known positive regulator of GR and PR in
addition to AR. Thus, direct targeting of the co-chaperone would target the activity of all three
receptors simultaneously, which have been shown to be expressed to higher levels in PCa and/or
to confer resistant to current antiandrogen treatments [159, 197-201]. Lastly, FKBP52 directly
regulates NFκB and inhibition of its signaling has recently been demonstrated to restore CRPC
responsiveness to ADT [202, 203]. These FKBP52-regulated AR functions are all through the
co-chaperone’s proline-rich loop interaction with the receptor; therefore, the loop has emerged as
a potential molecular target for pharmacological intervention. Unfortunately, the proline-rich
loop does not represent an ideal hydrophobic drug binding pocket, however, the PPIase catalytic
pocket underneath the loop does. The available co-crystal structure of FKBP12 bound to FK506
suggests that small molecules docked within the PPIase pocket could re-orient the proline-rich
loop conformation leading to the disruption of interaction with the receptor LBD at this surface.
Thus, the overall goal of this dissertation study was to develop and characterize a novel small
molecule targeting the FKBP52 PPIase pocket that leads to disruption of proline-rich loop
interactions between the co-chaperone and AR for the treatment of advanced PCa. Furthermore,
we aimed to develop a solution formulation of GMC1 and use the formulation to determine the
efficacy of GMC1 in a human prostate cancer xenograft mouse model.
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5.1 STRUCTURE-BASED IN SILICO SCREEN IS A VIABLE METHODOLOGY FOR IDENTIFICATION
OF GMC1 TARGETING FKBP52 PPIASE POCKET
As aforementioned, the FKBP52 proline-rich loop surface does not represent an ideal
hydrophobic drug binding site, but the PPIase pocket underneath the loop does. This catalytic
region is a well-characterized hydrophobic cavity that forms strong hydrophobic interactions
with ligands except a few polar residues, which are Asp68, Ile87 and Tyr113 in FKBP52, for
creating hydrogen bonds with binding molecules (Fig. 2.1).

We employed a FKBP52 PPIase

pocket-targeted in silico screen on a ZINC database with 3 million commercially available leadlike compounds and identified 40 structurally diverse hit compounds. We performed functional
AR-mediated luciferase assays on the compounds for their effect on FKBP52-regulated ARdependent activity. GMC1 was the resulting lead molecule that demonstrated a potent FKBP52specific inhibition of AR function with an IC50 value 0.6576 µM (Fig. 2.2b).
Interestingly, following the completion of the screen, we have observed that GMC1 is
structurally similar to a recently identified novel compound, D44, that targets the PPIase of an
FKBP protein from Plasmodium, which has been studied as a potential anti-malaria drug [266].
Similar to our efforts in finding a lead molecule, Harikishore et al. employed a structure-based in
silico library screening of commercially available compounds and identified D44.

The

inhibitor’s mode of action is through binding of the PPIase pocket of FKBP35 of malaria
parasites Plasmodium falciparum and Plasmodium vivax (PfFKBP35 and PvFKBP35) [266]. In
addition, D44 is a small molecule that antagonizes Plasmodium FKBP35 without interacting
with and activating the calcineurin pathway upon binding to FKBP as FK506 does. Therefore, it
would be interesting to assess whether GMC1 can elicit similar growth inhibition of the malaria
parasites as D44 by modulating PfFKBP35 and PvFKBP35 functions via binding to the PPIase
domain as they share sequence and structural similarities within canonical FKBP family
members including FKBP52.
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5.2 SMALL MOLECULE FKBP52 INHIBITOR GMC1 AS A POTENTIAL TREATMENT FOR
ADVANCED PCA
FKBP52 is a relevant factor in AR, GR, and PR-related physiology and diseases, which
have been firmly established in both in vivo and in vitro studies. The 52KO mouse models
demonstrated that in the absence of the co-chaperone, the animal displayed phenotypes that are
consistent with the insensitivity syndromes that result in defective AR, GR, and PR signaling.
Our data demonstrated that GMC1 is effective in inhibiting FKBP52-specific AR, GR and PRmediated activity (Fig. 2.2 and Fig. 3.1) suggesting its therapeutic potential to serve as a potent
drug candidate in treating diseases and/or averting side effects associated with current ADT
resulting from androgen, glucocorticoid, and progesterone insensitivity. Also, the data suggests
that GMC1 has the ability to deter the disease resistance that arises from cross-talk between the
receptors, which often occur in CRPC and confer resistance to antiandrogen treatments. It is
noteworthy that GMC1, a small molecule that has not been structurally optimized by SAR,
exhibited FKBP52-specific inhibitory effect on AR-regulated function at high nanomolar
concentration (Fig. 2.2b), which is comparable to what we observed in structurally optimized
MJC13. It suggests that disrupting the FKBP52 proline-rich loop interaction surface with AR is
a more powerful drug target than targeting the alternative binding site on the LBD. Given that
GMC1 does not share similar structural properties to the current antiandrogens (Flutamide,
Bicalutamide, and MDV3100), and does not bind to the AR LBD, we predict that it will not
produce the partial agonistic effects that are seen with the antiandrogens.
PSA, also known as kallikerin-related peptidase 3 (KLK3), is a chymotrypsin-like
kallikrein that is produced at very high levels by prostate cancer cells in comparison to normal
prostate secretory-luminal epithelial cells [267-269]. This protein has been used extensively as a
biomarker to screen for PCa, to detect recurrence following local therapies, and to monitor
response to systemic therapies for metastatic disease. Despite the current controversies over the
effectiveness of PSA as a PCa screening test, the fact that PSA levels do have a correlation with
prognosis of the disease is irrefutable. We employed ELISA analysis to assess GMC1 effects on
106

PSA secretion in 22Rv1 and LNCaP prostate cancer cells.

GMC1 exhibited a concentration-

dependent reduction in hormone-stimulated PSA secretion (Fig. 3.2a-b). Interestingly, the data
showed an inhibition of basal PSA activity in 22Rv1 cells, which might suggest that GMC1
could have effects on AR splice variants (Fig. 3.2c).

Moreover, the impairment of androgen-

stimulated PSA secretion from 22Rv1 cells was more potent as compared to LNCaP, which only
responds to hormone and displays DHT-dependent PSA production (Fig 3.2). Taken together,
these data suggest that GMC1 may be effective in inhibiting hormone-independent PSA
secretion as often occurs in CRPC.
GMC1 inhibitory effect on AR signaling was examined using PSA promoter as it is the
best characterized androgen-responsive model. As shown in Fig. 3.3a, the hormone-induced
PSA promoter activity was reduced in a concentration-dependent manner by our lead molecule.
GMC1 significantly suppressed the hormone-mediated AR transactivation activity at 30 µM and
higher concentrations of which is comparable to SAR optimized MJC13 and clinically used
Bicalutamide and MDV3100 (Fig. 3.3).

Our lead molecule GMC1 effectively reduced

transactivation of PSA promoter in LNCaP, which express the AR-T877A mutation, suggesting
that our molecule could be effective against Flutamide-resistant AR. In recent years, the AR
T877A mutant along with a series of acquired spontaneous mutations in AR LBD have
contributed to a phenomenon termed antiandrogen withdrawal syndrome (AWS), which is
characterized by a decline in serum PSA levels and a regression of tumors after discontinuation
of antiandrogen administration in patients with recurrent PCa [270, 271].

These acquired

mutations often broaden ligand specificity and confer an antagonist-to-agonist switch that drives
phenotypic resistance in CRPC. It would be interesting to perform transactivation assays to
assess GMC1 effects on antiandrogen agonist-switch AR mutants which include W741L/C
(Bicalutamide) [272], F876L (MDV3100) [163], H874Y (Flutamide) [273], etc. We expect our
lead molecule to maintain its antagonistic effect on the mutated AR and circumvent the AWS
occurrence given the molecular mechanism of GMC1 is targeting FKBP52 PPIase pocket to
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disrupt the proline-rich loop interaction surface with AR instead of binding to AR LBD as
current antiandrogens do.
Androgen signaling is through ligand-dependent AR activation leading to the modulation
androgen-regulated genes including AR, PSA, and FKBP51, which are essential for the
development of the prostate and also responsible for the pathogenesis of PCa. Therefore, they
have recently emerged as promising prognostic biomarkers for PCa and candidates for cancer
therapy. We examined the effects of GMC1 on the endogenous levels of androgen-responsive
AR, FKBP51 and PSA expressions using Western immunoblots and densitometry analyses in
prostate cancer cells (Fig. 3.4 and Fig. 3.5). Our data showed GMC1 promotes degradation of
AR in the presence of DHT (Fig. 3.4) and suppressed androgen-dependent AR-mediated PSA
and FKBP51 expressions in concentration-dependent manners (Fig. 3.5).

These results

demonstrate that GMC1 induced AR protein instability resulting in a reduced number of the
receptor molecules capable of binding hormone leading to decreased androgen-dependent AR,
PSA, and FKBP51 gene expression. This disrupts the FKBP51 positive feed forward mechanism
with AR and abolishes the amplification of AR signaling which often occurs in the low-hormone
conditions that happen during androgen ablation. Therefore, the data suggest GMC1 could be
effective in treating CRPC. It is interesting to note that GMC1 appears to have a greater
influence on 22Rv1 compared to LNCaP; it consistently requires lower concentrations to achieve
significant inhibition of ligand-dependent AR-regulated activities (Fig. 3.4 and Fig. 3.5).
Additionally, the lead molecule at high dose, 100 µM, was observed to reduce the expression of
the constitutively active truncated AR at approximately 80 kDa (Fig. 3.4a) and as
aforementioned, the decreasing basal PSA secretion level in 22Rv1 (Fig. 3.2a, inset). These
observations suggest that GMC1 could affect functions of constitutively active AR splice
variants, which are frequently expressed at high level in CRPC.
One of the hallmarks of cancer is uncontrollable cell proliferation, thus we carried out
cell proliferation assays with three prostate cancer cell lines: AR-positive LNCaP and 22Rv1
cells and AR-negative PC3 prostate cancer cells, to determine whether GMC1 affects tumor cell
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proliferation. Our lead molecule antagonized the proliferative effect of the synthetic androgen
R1881 without any significant effect on the growth of AR-negative PC3 cells at the same
concentrations (Fig. 3.6), which demonstrates that the inhibition of proliferation observed in ARpositive LNCaP and 22Rv1 cells was mediated through antagonism of AR. It was observed that
GMC1 appeared to affect the growth of LNCaP in the absence of R1881 at 75 µM and 100 µM,
which suggests that our molecule could be slightly cytotoxic at those concentrations. However,
the trend of GMC1 inhibiting cell growth in an androgen-dependent AR-mediated manner is
indisputable.

Additionally, the statistical analyses comparing the data points at higher

concentrations in the absence and presence of R118A demonstrated that GMC1 significantly
antagonized the hormone-dependent proliferative effect (Fig. 3.6b) and the observed
phenomenon was not due to cytotoxicity.
5.3 CONFIRMATION OF GMC1 BINDING TO THE PROPOSED SITE ON THE FKBP52 PPIASE
CATALYTIC POCKET
We attempted to prove that the FKBP52 PPIase pocket inhibitor GMC1 does directly
bind to the predicted target site in the hydrophobic cavity by performing a competitive FP assay
with a known FKBP inhibitor FK506 targeting the catalytic groove. Unfortunately, we did not
detect any competitive binding of GMC1 to the PPIase pocket due to the nature of its small size
and low binding affinity for the catalytic cavity compared to the control binder. Thus, in order to
verify that GMC1 directly binds to the predicted target site on the catalytic pocket, we designed
and constructed amino acid mutations that may alter the predicted binding site of the compound
while not affecting the FKBP52 potentiation of AR function.

We generated alanine point

mutations at D68, V86, I87, and Y113 in the full-length human FKBP52. Among these, three
mutants, FKBP52-D68A, V87A, and I87A maintained FKBP52-mediated AR function, while the
mutation at Y113 destroyed the co-chaperone-regulated receptor activity and was not considered
further (Fig. 4.1). GMC1 was tested on the three mutants and compared to the luciferase
activities obtained with AR and wild type FKBP52. There was a trend for GMC1 inhibition of
FKBP52-mediated AR function with the D68A mutation, suggesting that our lead molecule
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interacts weakly with the residue in the proposed FKBP52 PPIase pocket target site (Fig. 4.2a).
Unfortunately, I was not able to complete receptor-mediated luciferase assays of FKBP52-V86A
and I87A mutants at the time of dissertation completion to determine the effects of those
mutations have on AR function in the presence of GMC1. It would be interesting to see which
residue in the PPIase pocket significantly influenced GMC1 inhibitory function. Even if none of
the mutants strongly affect the inhibition, this does not mean that GMC1 has no interaction with
the predicted binding site. It simply could suggest that all three residues, D68, V86, and I87, are
required and equally important for GMC1 binding and displaying the potent inhibitory effects we
observed in vitro.
5.4 SOLUTION FORMULATION DEVELOPMENT AND EFFICACY OF GMC1 IN PRECLINICAL
CRPC ANIMAL MODEL
We successfully developed and optimized a co-solvent formulation allowing for in vivo
administration of GMC1 that is based on the compound’s physicochemical properties. The
optimal co-solvent system for GMC1 is with LP4 formulation (Table 4.3). It is stable and
suitable for further preclinical and clinical evaluations of safety and efficacy. The formulation
was successfully applied in a preliminary preclinical efficacy study in an androgen-independent
prostate cancer xenograft mouse model and showed significant regression of tumor size and
volume (Fig. 4.3). This proof-of-principle data demonstrates that inhibition of FKBP52-specific
activity via disrupting its proline-rich loop interaction with AR is an effective and promising
strategy in treating CRPC.
5.5 PROPOSED MECHANISM
Based on the in vitro evidence, it is hypothesized that binding of FKBP52 to the extreme
C-terminus of Hsp90 brings the proline-rich loop overhanging the FKBP52 FK1 domain in close
proximity to the receptor LBD leading to regulation of hormone binding and subcellular
localization. GMC1 interrupts this interaction by disrupting the architectural integrity of the
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loop, subsequently inducing dissociation of the mature chaperone complex and degradation of
AR via the ubiquitin/proteasome pathway (Fig. 5.1).
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Figure 5.1: Proposed Mechanism of Action of FKBP52-Specific Small Molecule Inhibitors
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Fig. 5.1: Proposed Mechanism of Action of FKBP52-Specific Small Molecule Inhibitors.
FKBP52 is a TPR-containing co-chaperone that plays a critical role in the chaperone-dependent
folding of SHRs to their functionally mature conformations that are competent for hormone
binding. It acts as a specific positive regulator of AR, GR, and PR functions through the
interaction of the proline-rich loop with the LBD of the SHRs. Upon ligand binding, the receptor
dimerizes and translocates to the nucleus, which then binds to the HRE and recruits other coregulators resulting in regulation of various physiological functions.

Direct targeting the

FKBP52 proline-rich loop interaction surface with the receptor LBD with small molecules (e.g.
GMC1) prevent ligand binding and leading to disruptions of SHR/Hsp90/FKBP52
heterocomplex such that client proteins are directed to the proteasome for degradation.
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5.6 CONCLUDING REMARKS
In this study, we have identified GMC1 as a first-in-class inhibitor directly targeting the
FKBP52 co-chaperone for the treatment of PCa. Give that GMC1 affects AR, GR and PR, but
has no effect on ER, the data support the predicted targeting of FKBP52 directly. We propose
that GMC1 interferes with the receptor-chaperone hetercomplex formation via binding to the
FKBP52 PPIase catalytic pocket in the FK1 domain, which induces re-orientation of the prolinerich loop overhang the cavity and disrupting the interaction surface with AR and/or causing a
spatial re-orientation within the asymmetrical intermediate chaperone complex preventing its
progression into mature stage of chaperone cycle. Further studies will be required to validate
this mechanism of action. Regardless, the consequences of inhibition of AR transactivation
activity, receptor-dependent gene expression, and androgen-stimulated proliferation and PSA
secretion in prostate cancer cell lines are indisputable. Due to its unique mechanism of action,
we believe GMC1 will be able to prevent aberrant AR signaling that is caused by cross-talk
between the signaling pathways (e.g. Wnt/β-catenin, NFκB), circumventing AR LBD mutationbased resistance arising from antiandrogen treatments (e.g. Flutamide, Bicalutamide,
MDV3100), and eluding the bypass of AR blockade via alternative SHR pathways (e.g. GR,
PR). We also believe GMC1 is a more potent and effective drug for the treatment of CRPC than
MJC13, Flutamide, Bicalutamide, and MDV3100, thereby filling a major unmet need in prostate
cancer therapy. Additionally, GMC1 could serve as a second line therapy for CRPC previously
treated with ADT and/or could be administered concurrently with antiandrogens to mitigate
undesirable side effects and resistance. Furthermore, given the functional roles of FKBP52 in
AR, GR, and PR-specific phenotypes and its elevated expression in ER-negative breast tumors,
GMC1 also represents an attractive treatment option and/or target for other endocrine-associated
diseases, such as male contraception, obesity/metabolic syndrome, stress and depression, and
ER-negative breast cancer.
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5.7 FUTURE DIRECTIONS
There is incontrovertible evidence that the onset of CRPC coincides with the renewed AR
signaling even without androgen stimulation, and the expression of constitutively active AR
splice variants are commonly increased in recurrent PCa following castration and continue to
drive tumor progression in the face of potent AR LBD inhibitory agents. Thus, we would like to
further investigate and characterize the inhibitory effects of GMC1 on androgen-independent
prostate cancer cell lines (e.g. VCaP), the constitutively active AR splice variants (e.g. AR-V7),
and the receptor-transcription activation functions that arise from spontaneous mutations in the
AR LBD (e.g. W741L/C, F876L, and H874Y) that often confer antiandrogens the antagonist-toagonist switch that drives AWS in CRPC.

Studies have shown that β-catenin and NFκB

signaling pathways often cross-talk with AR contributing to CRPC development and
progression. β-catenin and NFκB have also been found to interact directly with FKBP52. Thus,
it would be interesting to assess GMC1 effects on the stability and interactions between SHRFKBP52 heterocomplex with β-catenin and/or NFκB. In addition, we would like to determine
the X-ray crystallographic structure of the FKBP52 PPIase pocket in the FK1 domain in complex
with GMC1 and perform an SAR analysis of our lead molecule, from which we will gain
structural insights into the mode of action of our compound and improve its efficacy, potency,
and solubility.
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GLOSSARY
AAV – Adeno-associated virus
Ab – Antibody
AD – Alzheimer’s disease
ADP – Adenosine diphosphate
ADT – Androgen deprivation therapy
AF2 – Activation function 2
Aha1 – ATPase homologue 1
AIS – Androgen insensitivity syndrome
ANOVA – Analysis of variance
AP – Alkaline phosphatase
APP – Amyloid precursor protein
AR – Androgen receptor
ARE – Androgen response element
ATCC – American type culture collection
ATP – Adenosine triphosphate
AWS – Antiandrogen withdraw syndrome
Aβ – Beta-amyloid
BAG-1 – Bcl-2-associated athanogene
BF3 – Binding function 3
BSA – Bovine serum albumin
Ca2+ - Calcium
CaM – Calmodulin
CD - Cyclodextrin
CHIP – Carboxyl terminus of Hsp70-interacting protein
CKII – Casein kinase II
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CO2 – Carbon dioxide
CRPC – Castration-resistant prostate cancer
CS – Charcoal-stripped
CSC – Cancer stem cell
Cu – Copper
CuBD – Copper binding domain
Cyp40 – Cyclophilin 40
DBD – DNA binding domain
DEX - Dexamethasone
DHT – Dihydrotestosterone
DMA – N, N-dimethylacetamide
DMSO – Dimethyl sulfoxide
DOC – Deoxycorticosterone
E2 - 17β-estradiol
EC50 – Half maximal effective concentration
EDTA – Ethylenediaminetetraacetic acid
ELISA – Enzyme-linked immunosorbent assay
EPLuc – Enhancer/promoter luciferase
ER – Estrogen receptor
ERE – Estrogen response element
EtOH – Ethanol
FBS – Fetal bovine serum
FK1 – FKBP12-like domain1
FK2 – FKBP12-like domain 2
FKBP12 – 12-kDA FK506-binding protein
FKBP35 – 35-kDa FK506-binding protein
FKBP38 – 38-kDa FK506-binding protein
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FKBP51 – 51-kDa FK506-binding protein
FKBP52 – 52-kDa FK506-binding protein
PfFKBP35 – Plasmodium falciparum FKBP35
PvFKBP35 – Plasmodium vivax FKBP35
FP – Fluorescence polarization
FRET – Fluorescence resonance energy transfer
FTDP – Fronto-temporal dementia and parkinsonism linked to chromosome 17
GAPDH – Glyceraldehyde-3-phosphate dehydrogenase
GR – Glucocorticoid receptor
GRIP1 – Glutamate receptor-interacting protein 1
GSK3β – Glycogen synthetase kinase 3β
GTP – Guanosine triphosphate
HEPE - 12S-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid
HIP – Hsp70-interacting protein
HOP – Hsp70/Hsp90 organization protein
HP-β-CD – 2-hydroxypropyl-β-cyclodextrin
HRE – Hormone response element
Hsp – Heat shock protein
IC50 – Half maximal inhibitory concentration
ID4 – Inhibitor of differentiation 4
IRF-4 – Interferon regulatory factor 4
KLK3 – Kallikrein-related peptidase 3
LBD – Ligand binding domain
LC-MS/MS – Liquid chromatography-mass spectrometry and liquid chromatography-tandem
mass spectrometry
logP – Logarithm of partition coefficient
LRH-1 – Liver receptor homolog-1
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MAP – Microtubule-associated protein
MD – Middle domain
MEF – Mouse embryonic fibroblast
52KO MEF - Mouse embryonic fibroblast cells from homozygous FKBP52 knockout embryos
MEM/EBSS – Minimal essential media/Earle’s balanced salt solution
MMFF – Merck molecular force field
MMTV – Mouse mammary tumor virus
MOE – Molecular operating environment
M-PER – Mammalian protein extraction reagent
MR – Mineralocorticoid receptor
NEAA – Nonessential amino acid
NFT – Neurofibrillary tangle
NLS – Nuclear localization signal
NRAM – Nuclear receptor alternative-site modulator
NTD – N-terminal domain
OPLS – Optimized potential for liquid simulations
P4 – Progesterone
PBS – Phosphate buffered saline
PCa – Prostate cancer
PCR – Polymerase chain reaction
PDB – Protein data bank
PHF – Paired helical filament
PEG 300 – Polyethylene glycol 300
PEG 400 – Polyethylene glycol 400
PPIase – Peptidyl-prolyl cis/trans isomerase
PR – Progesterone receptor
PRDX6 – Peroxiredoxin-6
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PSA – Prostate specific antigen
PVDF – Polyvinylidene difluoride
RLU – Relative light unit
RMSD – Root-mean-square deviation
RPM – Revolution per min
RPMI – Roswell Park Memorial Institute
S.D. – Standard deviation
SAR – Structure-activity relationship
SGTA – Small glutamine-rich tetracopeptide repeat-containing protein alpha
SHR – Steroid hormone receptor
shRNA – Shor hairpin RNA
SP – Sum-of-pairs
SRC-2 – Steroid receptor co-activator 2
α-Syn – α-Synuclein
TBST – Tris-buffered saline containing tween
TCF – T-cell factor
TIF2 – Transcriptional mediators/intermediatry factor 2
TMB – 3,3’,5,5’-Tetramethylbenzidine
TPR – Tetratricopeptide repeat
TRPC – Transient receptor potential channel
TRPL – Transient receptor potential-like
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